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Abstract
PCOS, a heterogeneous disorder characterized by cystic ovarian morphology, androgen excess, and/or irregular
periods, emerges during or shortly after puberty. Peri- and post-pubertal obesity, insulin resistance and consequent
hyperinsulinemia are highly prevalent co-morbidities of PCOS and promote an ongoing state of excess androgen.
Given the relationship of insulin to androgen excess, reduction of insulin secretion and/or improvement of its
action at target tissues offer the possibility of improving the physical stigmata of androgen excess by correction of
the reproductive dysfunction and preventing metabolic derangements from becoming entrenched. While lifestyle
changes that concentrate on behavioral, dietary and exercise regimens should be considered as first line therapy
for weight reduction and normalization of insulin levels in adolescents with PCOS, several therapeutic options are
available and in wide use, including oral contraceptives, metformin, thiazolidenediones and spironolactone.
Overwhelmingly, the data on the safety and efficacy of these medications derive from the adult PCOS literature.
Despite the paucity of randomized control trials to adequately evaluate these modalities in adolescents, their use,
particularly that of metformin, has gained popularity in the pediatric endocrine community. In this article, we
present an overview of the use of insulin sensitizing medications in PCOS and review both the adult and (where
available) adolescent literature, focusing specifically on the use of metformin in both mono- and combination
therapy.
Background
Recognition of the highly prevalent association between
PCOS and insulin resistance (IR) has stimulated research
into the mechanism(s) behind this relationship, defining
the metabolic, cardiovascular, and reproductive conse-
quences of the IR, and evaluating therapies that target IR.
Much of the current therapeutic paradigm incorporating
insulin sensitization is derived from studies in adult
women; application to the adolescent requires critical eva-
luation of the data supporting insulin sensitizer use in this
age group. Although not intended as a comprehensive
review of PCOS therapy, this report will discuss the
options available for the treatment of adolescents with
PCOS, with focus on the possible efficacy and costs of
insulin sensitizing agents in comparison to more tradi-
tional therapies for PCOS.
PCOS is a heterogeneous condition affecting 7-10% of
women worldwide [1,2], irrespective of ethnic background
[3], making it the most common endocrine disorder
among reproductive-aged women. The 2003 Androgen
Excess Society (AES) consensus required two of the fol-
lowing three criteria as necessary for the diagnosis: hyper-
androgenism, ovarian dysfunction (oligo- or anovulation),
and/or a polycystic ovary [4]. Summarizing the report of
the recent 4th annual meeting of the Androgen Excess and
PCOS Society [5], Yildiz and Azziz noted the difficulty in
defining certain sub-phenotypes of PCOS, such as women
with irregular menstrual cycling and polycystic ovarian
morphology without evidence of hyperandrogenism (pre-
viously considered essential for the diagnosis).
While hyperandrogenism is central to classically
defined PCOS pathophysiology [6-8], and testosterone
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and DHEA-S are increased in up to 75% of PCOS
patients, obesity and IR are frequently associated [9-11].
As many as 60% of women with PCOS have BMI values
in the overweight or obese range [2] and 70% demon-
strate IR and diabetes beyond that predicted by weight
alone [12-14]. Hyperinsulinemia consequent to obesity
and IR places women with PCOS at far greater risk to
develop type 2 diabetes (T2DM) than healthy controls
[15]: 15-36% of all T2DM reported in women, irrespec-
tive of age, is found in association with PCOS
[14,16-19]. While most PCOS women demonstrate pre-
served or even exaggerated insulin secretory responsive-
ness, many PCOS women, particularly those with a
family history of T2DM, manifest secretory impairment
and glucose intolerance. In addition, the typically gra-
dual transition from impaired glucose tolerance (IGT)
to overt T2DM may be accelerated 5 to 10-fold in
women with PCOS [20,21]. Legro demonstrated that
40% of women with PCOS had glucose intolerance, and
7.5% of these women manifested frank T2DM, preva-
lence rates 5-7 fold higher than those reported in popu-
lation-based studies of women aged 20-44 [22]. 1/3 of
women with PCOS fulfill criteria for the diagnosis of
the metabolic syndrome (MBS) [11]. These associated
metabolic derangements greatly increase a woman’s life-
time risk to develop T2DM and cardiovascular co-mor-
bidities [23,24]. Underscoring concerns about the strong
association between IR and PCOS, the AES recently
recommended that all patients with PCOS be tested for
IGT with a 2-h oral glucose tolerance test every 2 years,
and annually if evidence of IGT or additional risk fac-
tors for emergence of T2DM is identified. Moreover, the
AES position statement proposed that PCOS patients
with IGT be treated with intensive lifestyle modification
and weight loss, and considered for treatment with insu-
lin-sensitizing agents, even before the onset of overt
T2DM [25].
The association between insulin and androgen excesses:
history and cellular mechanisms
The association between disordered carbohydrate meta-
bolism and excessive androgen action in women was first
reported in 1921 [26] as “the diabetes of bearded women
(diabète des femmes à barbe)”, preceding Stein and
Leventhal’s formal description of PCOS [27]. A half-cen-
tury later, researchers described a group of adolescent
girls with the constellation of hyperandrogenism, severe
IR, and acanthosis nigricans, a dermatologic manifesta-
tion of hyperinsulinemia (HAIR-AN, or “type A” IR) [28].
A subset of these patients was shown to have mutations
of the insulin receptor [29-31]. A second, distinct form of
insulin insensitivity associated with androgen excess in
post-menopausal women, designated “type B” IR, results
from anti-insulin receptor antibodies [32]. Nevertheless,
population analyses of PCOS women consistently fails to
demonstrate either of these forms of IR as common to
the disorder [33].
Burghen and colleagues observed a positive correlation
between basal and glucose-stimulated insulin and andro-
gen levels in PCOS, independent of weight, suggesting a
causal relationship between hyperinsulinism and hyperan-
drogenism [34]. An abundant literature corroborates
strong associations between insulin and various circulating
androgens in PCOS [35-37], particularly free testosterone
levels [38-40]. Emphasizing the apparently singular nature
of the abnormalities of insulin action in PCOS, a signifi-
cant inverse relationship exists between insulin sensitivity
and testosterone levels for women with PCOS-associated
metabolic derangements a relationship independent of
BMI [41-43] whose underlying mechanism remains poorly
defined.
More recent reports [37,44] confirm a degree of IR in
non-obese women with PCOS not found in lean controls.
Ehrmann demonstrated that the striking relationship
between PCOS androgen excess and MBS can be linked
causally to hyperinsulinemia and thus underlying IR [11];
oscillatory glucose infusions verified concurrent defects in
b-cell entrainment in women with PCOS [45]. Insulin
secretory defects are more pronounced in PCOS women
having first-degree relatives with T2DM [21,45], and
appear to develop earlier in the evolution of glucose intol-
erance in women with PCOS than in the general popula-
tion. Despite these quantitative defects in b-cell function,
women with PCOS generally maintain normal glucose tol-
erance, in contrast to that observed in classical T2DM
[46]. That weight reduction alone often fails to resolve the
insulin secretory defects in PCOS further emphasizes the
uniqueness of the metabolic derangements in this syn-
drome [36]. The impairment of insulin dynamics found in
PCOS thus appears to differ from that observed in T2DM,
both with respect to peripheral insulin sensitivity and b-
cell secretory capability.
The hyperinsulinemic response to peripheral IR
observed in women with PCOS is frequently modest
[47,48]. Corroborating data involving more exacting mea-
sures of insulin sensitivity are less consistent, with some
studies reporting decreased insulin sensitivity in obese,
but not lean PCOS, despite comparably elevated insulin
levels [47,49]. These discrepancies may reflect differences
in methodology used to quantify insulin sensitivity (e.g.,
fasting measures of glucose and insulin [HOMA,
QUICKI]), insulin sensitivity index [ISI], minimal model-
ing of frequently-sampled IV glucose tolerance testing
[FSIGT], insulin clamps). Surrogate measures based on
fasting insulin and glucose correlate poorly with gold
standard techniques such as the euglycemic clamp in the
assessment of insulin dynamics in adult PCOS [50], 2-hr
glucose levels in adolescents with PCOS [51], and FSIGT
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in healthy children [52]. Moreover, the excess abdominal
fat mass observed in both obese and lean PCOS likely
contributes to attenuated insulin sensitivity [53-57].
In response to whole body insulin insensitivity, a more
permissive transduction of the insulin signal at the ovar-
ian thecal level may contribute to the pathogenesis of
the androgen excess [reviewed in [16]], amplified even
in the absence of markedly elevated circulating levels of
insulin. Human theca cells possess the full complement
of insulin signaling elements and insulin increases thecal
testosterone biosynthesis in dose-dependent fashion
[58,59]; thus, insulin exerts a direct effect on androgen
synthesis. In both obese and lean PCOS, insulin aug-
ments CYP17 activity, increasing androgen production
[60,61]. Serine phosphorylation of both the insulin
receptor and regulatory steroidogenic enzymes by as-yet
unidentified serine kinase has been proposed to underlie
both cellular IR and increased ovarian androgenesis in
women with PCOS [62]. Insulin also suppresses hepatic
sex hormone binding globulin (SHBG) production
[63,64], with a consequent increase in free androgen
levels. Centrally, androgen excess may reduce hypothala-
mic feedback inhibition, resulting in increased GnRH
pulsatility, particularly during puberty [65-67]. Increased
insulin does not appear to govern gonadotropin secre-
tion directly: PCOS women treated with pioglitazone
demonstrate improved insulin sensitivity without altera-
tions in LH pulse frequency or amplitude, or gonadotro-
pin responses to GnRH [68]. Conversely, some data
support a blunting of baseline LH and LH pulse ampli-
tude in obese PCOS women, suggesting perhaps that
the effect of IR (and consequent insulin excess) is to
inhibit LH secretion [69-72].
The Heritability of PCOS and IR
A genetic etiology for PCOS has been established on the
basis of familial clustering [6,21,43-45], with heritability
estimates as high as 0.79 [73]. Genetic studies of PCOS
typically extend preliminary genome-wide association
studies (GWAS), seeking correlations between specific
allelic variants of GWAS-nominated genes and PCOS
and/or its co-morbidities (e.g., IR) [74]. An exhaustive
discussion of the candidate genes identified is beyond the
scope of this review and few genes have been broadly
accepted as causative, due to lack of replication in larger
studies [75-80]. The success of these studies has been
limited by the lack of consensus in diagnostic criteria
resulting in broad phenotypic heterogeneity (described
above), the limited sample sizes of many studies, and the
difficulty in identifying among kindreds a PCOS pheno-
type in males and late adolescent women. Concurrent
variation at multiple genetic loci (characteristic of the
inheritance patterns of many common complex disor-
ders) and lifestyle/environmental factors exerting
epigenetic influences on emerging disease further con-
found efforts to define PCOS heritability.
Family studies of adult female first-degree relatives of
PCOS probands demonstrate that the prevalence of
PCOS and associated abnormalities of insulin dynamics
are increased, consistent with a dominant mode of trans-
mission [81-83]. Kahsar-Miller [84] determined the pre-
valence of PCOS in first-degree relatives of women with
PCOS to be as high as 35% (mothers) and 40% (sisters), 5
times that observed in the general population. Both IR
and T2DM are increased in the parents of women with
PCOS compared to the parents of women in the general
population [85]. Mothers [86] and sisters [87] of PCOS
probands exhibit menstrual irregularities, androgen
excess, aberrant lipoprotein profiles, and MBS, with pro-
found defects in insulin secretory function and sensitivity
[88]. First-degree male relatives of PCOS women also
demonstrate increased adrenal androgens (DHEA-S), IR,
endothelial dysfunction and MBS [89-91]. Recent cross-
sectional studies by Sir-Peterman demonstrated that
daughters of women with PCOS manifest increased 2-hr
insulin concentrations (despite preserved glucose toler-
ance) vs. controls across the entirety of pubertal matura-
tion [92,93]. Conversely, Kent observed only late pubertal
hyperinsulinemia in girls predisposed to PCOS [94].
Neither of these studies tracked subjects longitudinally
into young adulthood; thus, the causal relationship
between disordered insulin action and a permanent,
post-pubertal state of androgen excess remains unproven.
Adolescent IR and post-pubertal androgen excess
Although biochemical evidence of ovarian hyperandro-
genism in PCOS is detectable shortly after pubertal onset
[95], consequent menstrual irregularity is often underap-
preciated, masked by the frequent acyclicity of post-
menarchal adolescence. Thus, oligomenorrhea may
escape recognition as pathologic until young adulthood.
The physiological IR that typifies mid-pubertal matura-
tion delays timely recognition of metabolic derangements
that precede and promote hyperandrogenism [38]. Peri-
pubertal metabolic dysfunction is one of the first pheno-
typic traits observed in adolescent girls who develop
PCOS [96,97]. Lewy demonstrated ~ 50% reduction in
insulin sensitivity in adolescents with PCOS and con-
cluded that profound metabolic derangements must
already exist early in puberty [98]. Apter reported that
adolescents with functional ovarian hyperandrogenism
(FOH) exhibit disproportionate, early pubertal increases
in mean serum insulin levels [99]. Abnormal insulin
dynamics are frequently established by the time phenoty-
pic features of PCOS (hirsutism, cystic acne) emerge in
late adolescence, irrespective of subject BMI [100]. Study-
ing a cohort of girls with premature adrenarche, whose
androgen profiles are reminiscent of PCOS, Ibanez
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[101-105] observed increased insulin levels and glucose
intolerance throughout maturation. Ovarian hyperandro-
genism consistently follows menarche, subsequent to the
emergence of IR, supporting the premise that IR pro-
motes dysregulated ovarian androgen production
[106,107]. In girls predisposed to PCOS hyperinsulinemia
precedes androgen excess [92], suggesting the primacy of
metabolic dysregulation in the ontogeny of hyperandro-
genism. Overweight and obese adolescent girls, posses-
sing higher circulating insulin levels than lean
counterparts [54,66,108], also exhibit elevated androgens,
further predisposing them to PCOS [109,110].
Earlier recognition of permanent states of hyperandro-
genism necessitates consideration of treatment algorithms
proposing earlier intervention to prevent establishment of
metabolic, cardiovascular, and reproductive sequelae that
manifest in young adulthood. However, long-term
outcomes data to support the most cost-effective manage-
ment, especially in the adolescent population, are lacking.
A variety of therapeutic modalities are currently employed
in the treatment of PCOS: oral contraceptives (OCPs),
insulin sensitizing medications (metformin, thiazolidene-
diones), and agents that exert anti-androgen effects (both
androgen receptor blockade and 5a-reductase inhibition),
alone or in combination (Table 1). Therapy aimed at redu-
cing androgen over-production in PCOS fails to amelio-
rate co-morbid IR: no significant improvement in insulin
dynamics is observed following long-term treatment of
adolescents with PCOS with GnRH analogues [111-114].
Similarly, treatment with anti-androgens fails to rectify
metabolic derangements in PCOS patients treated
[115-117]. Reduction of hyperandrogenemia thus has little
effect on IR. Conversely, as will be discussed below, insulin
sensitization decreases both androgen and insulin excess,
suggesting that, in selected patients with PCOS, insulin
excess may be fundamental to the development of
hyperandrogenemia.
Adolescents with emerging PCOS face considerable life-
long morbidity: i) 2/3 of late adolescents with menstrual
irregularity due to FOH remain oligomenorrheic into
adulthood [118]; (ii) adolescents with PCOS are 4-5 fold
more likely to develop MBS than age- and BMI-matched
control girls [96]; and (iii) potentially life-threatening car-
diovascular dysfunction has its origins during pubertal
maturation, and demonstrable by young adulthood
[119-121]. The abundant evidence suggesting that IR and
resultant hyperinsulinemia facilitate ovarian hyperandro-
genism is central to the argument for the use of insulin
sensitizers to treat adolescents with PCOS [122], when
treatment might preclude adverse metabolic, reproductive
and cardiovascular outcomes.
The remainder of this document will: 1) discuss the pri-
mary modalities available for the treatment of PCOS; 2)
review the literature that compares and contrasts their effi-
cacy, alone or in combination; 3) where available, evaluate
the data concerning treatment of a late adolescent PCOS
population; and 4) consider whether insulin sensitization,
given the role insulin may play in promoting androgen
production, should be considered as first-line therapy for
the treatment of adolescents with PCOS.
Modalities for Treatment of PCOS
Therapy for PCOS becomes necessary in adults in order
to induce ovulatory cycles and fertility, and to improve
cosmetic appearance (i.e., reduction of hirsutism and
acne). At the same time, it is important to address obesity
and associated metabolic complications, which include:
1) endothelial dysfunction and inflammation, 2) an
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atherogenic serum lipoprotein profile, 3) increased cor-
onary artery calcification, 4) nonalcoholic fatty liver dis-
ease and nonalcoholic steatohepatitis, and 5) obstructive
sleep apnea. Therapeutic options include lifestyle modifi-
cation, combine oral contraceptive pills, androgen recep-
tor antagonists, insulin-lowering medications (e.g.,
metformin and thiazolidinediones) (Table 1). In adoles-
cents with PCOS, induction of ovulatory cycles and ferti-
lity is of lesser importance, although it is important to
induce some element of menstrual cyclicity in order to
optimize endometrial health. Improving cosmetic appear-
ance and reduction of weight and obesity- associated
metabolic complications are important therapeutic
targets.
Lifestyle modification and weight loss
The first line of therapy in obese adolescents with PCOS
is lifestyle modification and weight loss. In addition to an
improvement in metabolic co-morbidities of obesity, this
would be expected to reduce insulin levels and increase
insulin sensitivity, resulting in a decrease in LH and
androgen levels. Behavioral, exercise and dietary modifi-
cations should therefore be encouraged from the initial
encounter, particularly in adolescents, to optimize
healthy habits before adulthood, and while these changes
are still possible and preventive.
Adult women with PCOS
Salmi reported improvement in almost every clinical vari-
able associated with PCOS after weight loss [123], and stu-
dies have demonstrated that even modest reductions in
weight in the range of 2-7% are successful in improving
ovulatory function in at least some adult women with this
condition [124-126]. Modest weight reductions with
improved fitness are as effective as more drastic reductions
in weight to reverse metabolic dysfunction associated with
PCOS and ovulatory function in adult women [127].
Recently, Palomba reported a decrease in IR with asso-
ciated improvement in menstrual cyclicity, fertility, SHBG,
and androgen levels in adults with PCOS randomized to
either a structured training program or a hypocaloric
hyperproteinemic diet [128]. The authors posited that
improved insulin sensitivity was integral to these changes
albeit brought about by different mechanisms and inter-
ventions. In contrast, Hoeger reported increases in ovula-
tion rates only after weight loss [124]. Kiddy similarly
reported that weight loss of at least 5% (with a 1000 cal-
orie, low fat diet for 6-7 months) was necessary to increase
SHBG, decrease insulin levels and improve reproductive
function in adults with PCOS [126]. Whereas the degree
of IR in PCOS is greater than that predicted by BMI alone,
nearly half of PCOS women are not obese [129] and the
degree of visceral adiposity alone is inadequate to explain
differences in insulin sensitivity between PCOS and nor-
mal women, suggesting that weight loss by itself may be
insufficient to improve ovarian function in the sub-popula-
tion of lean women with PCOS[130].
Adolescents with PCOS
Consistent with studies in adults, pediatric studies have
demonstrated decreases in adrenal and ovarian andro-
gens with weight loss in both obese pre-pubertal and
pubertal girls [131,132], and a 59% reduction in free
androgen index with a 122% increase in SHBG levels in
obese adolescent girls with PCOS [133]. In the last study,
changes were observed despite only modest weight
reductions. Importantly, increases in SHBG were much
greater in girls who lost weight compared to those who
did not.
However, lifestyle modifications are difficult to sustain
and are associated with high degrees of recidivism. One
study reported a drop out rate of almost 40% in adult
subjects enrolled in a study that included intensive life-
style modification [124]. In a study of adolescents with
PCOS, 30% of subjects enrolled into an intensive lifestyle
modification program dropped out; 40% attended less
than 50% of the sessions and demonstrated no weight
change [133]. Therefore, in most instances, pharmacolo-
gical therapy for PCOS becomes necessary. Available
data indicate that in adult women with PCOS, the addi-
tion of metformin therapy to lifestyle modification
appears more effective than lifestyle changes alone in
maintaining weight loss and in ameliorating metabolic
complications of obesity [134,135]. In addition, marked
improvements in androgen profiles on the basis of a regi-
mented diet and exercise program would be less antici-
pated in those adolescents with PCOS and normal body
composition.
A potential alternative to pharmacological therapy,
which we discuss subsequently, particularly in extremely
overweight adolescents, is weight reduction surgery. Surgi-
cal weight loss procedures have the advantage of more
extensive and persistent weight loss than dietary or exer-
cise programs. With the emerging popularity of bariatric
surgery to reduce weight in very obese adults, studies have
examined the effectiveness of the surgical approach in
reducing the severity of clinical features associated with
PCOS in these patients. Two studies reported that all
adult women with PCOS undergoing gastric bypass sur-
gery resumed menses in the subsequent months, with a
significant improvement in hirsutism scores [136,137] and
reductions in androgen levels [137]. In one study, about
77% of women reported moderate to complete resolution
of hirsutism [136] and in another study, a 48% reduction
in hirsutism scores and a 62.5% reduction in free testoster-
one levels was reported [138]. Bariatric surgery has been
successfully implemented in a few hundred adolescents
[139]; as more adolescents undergo these procedures, the
necessary data regarding their effectiveness in treating
associated PCOS will become available. At this time, the
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possible morbidity associated with this type of surgery lim-
its weight loss surgery to select adolescents with extremely
high BMI and associated complications, and centers with
an appropriate team-centered approach.
Use of Oral Contraceptive Pills (OCPs) in PCOS
OCPs are considered to be among the primary treatment
options for both adult and adolescent women with
PCOS, particularly for those who did not wish to become
pregnant [140]. These agents produce regular menstrual
cyclicity, lower the risk of endometrial hyperplasia, and
dramatically improve acne and hirsutism. Most com-
monly used OCPs contain both an estrogenic component
(typically ethinyl estradiol, in doses ranging from 15 to
50 μg) and a progestin with variable potency and andro-
genicity [141]. Oral contraceptives improve symptoms
through a variety of mechanisms. Estrogens increase the
production of SHBG, resulting in a decrease of circulat-
ing free androgens, as well as their bioavailability [142].
Progestins protect the endometrium against hyperplasia
induced by unopposed estrogen stimulation. The andro-
genicity of the progestins, mediated through differential
androgen receptor binding and blockade [143] or inhibi-
tion of 5a-reductase activity [144,145], varies depending
on the dosage used and on androgen measurement
indices. Some progestins, such as drospirenone and
cyproterone acetate, have proven anti-androgenic effects
and therefore may yield added benefit in PCOS [146].
Finally combined OCPs suppress luteinizing and follicu-
lar stimulating hormones, resulting in reduced ovarian
stimulation and androgen production. However, none of
these mechanisms directly affect IR [147].
Despite the popularity of OCP use and the number of
available combinations, studies contrasting the different
agents in head to head comparison are few, their results
often equivocal (and contradictory), and few have included
an adolescent population. The outcome measures assessed
among different studies vary considerably, making the
comparison of results difficult. Van der Vange [148] ran-
domized 70 healthy adult women to 7 different OCPs pre-
parations for 6 months; and because the absolute free
testosterone levels were similar in all 7 groups, they con-
cluded that these preparations would be of equal benefit
in the treatment of hyperandrogenic symptoms. A more
recent study compared the effect of 4 OCPs with different
progestins on hormonal parameters in 40 women with
PCOS over 3 months [149]. They found that all 4 proges-
tins combined with the same dose of ethinylestradiol
resulted in significant decrease in testosterone (total and
free), androsteredione, dehydroepiandrosterone sulfate;
but drospirenone and chlormadinone had more pro-
nounced effects than desogestrel and gestodene. However,
clinical effect was not assessed. In a 12-month randomized
control trial of adolescents with PCOS testing the efficacy
of combined pills with desogestrol or cyproterone acetate
as the progestin, the preparations were found to have simi-
lar effects on hirsutism and androgen levels [150]. Finally,
the benefit of combining GnRH analog with OCPs to sup-
press LH pulsatility and androgen production has been
investigated, particularly with respect to moderate-severe
hirsutism (see below); little added benefit was observed
despite the marked increase in cost over OCPs alone
[39,151].
Independent of their effect in improving the signs and
symptoms of PCOS, OCPs possess additional benefits that
may support a decision for their use in this age group. The
contraceptive potential of birth control pills is a para-
mount consideration: 1/3 of teenage girls with PCOS
reported being sexually active in one recent study [152].
Women with PCOS may be at increased risk of developing
gynecologic cancers [153-155], and the use of OCPs
reduces the risk of both ovarian [156] and uterine cancer
[157] in the general population of women. Conversely, a
recent Cochrane review on the treatment options for
women with PCOS found insufficient data for the efficacy
of OCP in preventing endometrial cancers in this adult
population [158].
Regardless of their potential benefits, use of OCPs fails
to diminish IR in PCOS and may actually be associated
with long-term metabolic derangements, such as glucose
intolerance, abnormal lipid profiles and cardiovascular dis-
ease. Recent work by Mastorakos showed that a 12-month
use of newer OCPs containing either desogestrel or cypro-
terone as progestin was associated with decreased insulin
sensitivity and increase total, LDL and HDL cholesterol
and variable changes in triglycerides in adolescents with
PCOS [150,159]. Two recent meta-analyses have linked
current use of low dose OCPs in women without PCOS to
more than a doubling of the risk of myocardial infarction
(risk estimates 2.12 (95% confidence interval (CI) = 1.56,
2.86) [160] and 2.48 (95% CI: 1.91-3.22) [161]. Although
the use of OCPs is associated with an overall increased
risk of adverse cardiovascular events (e.g., venous throm-
bosis and myocardial infarction) among all users, the abso-
lute risk remains minimal in adolescents, even in the sub-
population using tobacco [162,163]. While newer OCPs
containing less androgenic progestin agents have the
potential for less deleterious impact on IR and lipid profile,
an insufficient number of adolescent subjects receiving
OCPs (and anti-androgen) monotherapy have been stu-
died to draw definitive conclusions about their long-term
safety. Moreover, longitudinal studies have not yet been
conducted among the population of women with PCOS
receiving OCPs, adult or adolescent; thus, the potential
exists for the excessive use of OCPs to exacerbate the
underlying metabolic derangements prevalent in PCOS,
thereby augmenting the subsequent risk for adverse cardi-
ovascular outcomes. Finally, there may be social, ethnic
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and/or religious stigmata associated with the use of OCPs
in some adolescent populations. These concerns have led
to a consideration of other approaches for adolescents
with PCOS, and specifically, treatment that concurrently
targets IR.
Studies of Insulin Sensitizers and Insulin Lowering Drugs
in Adolescents with PCOS
These medications act to reduce insulin levels (metformin)
and increase insulin sensitivity (metformin and thiazolide-
nediones), thus treating the metabolic co-morbidities asso-
ciated with PCOS and obesity. Reductions in insulin levels
effect a concurrent reduction in androgen levels (discussed
subsequently) and induce menstrual cyclicity and ovula-
tory cycles in a majority of those treated. However, recent
guidelines recommend that (i) clomiphene (rather than
metformin) should be used to induce ovulatory cycles in
adult women with PCOS desiring fertility, and (ii) hyper-
androgenism causing hirsutism should be treated with
estrogen-progestin combination pills, with addition of an
androgen receptor blocker after six months if the former
are not effective in reducing hirsutism (reviewed in [164]).
The role of insulin-lowering agents and sensitizers such as
metformin in PCOS may be limited to optimizing weight
loss when used with lifestyle modification, and in treat-
ment or amelioration of metabolic complications includ-
ing hyperlipidemia and reduction of levels of pro-
inflammatory cytokines, Additional reasons to consider
the use of metformin or thiazolidenediones rather than
combined oral contraceptive pills may include the pre-
sence of Factor V Leiden mutations, which increase the
risk of thromboembolic episodes with estrogen use, or an
intolerance, non-adherence, or refusal to use estradiol-pro-
gesterone (E2-P) combination pills. The paucity of rando-
mized controlled studies of the various therapeutic
options in adolescents with PCOS makes it difficult to
develop therapeutic guidelines in this younger population.
In subsequent sections, we review available data in adoles-
cents, and some data from adults with PCOS, that com-
pare the efficacy of metformin and thiazolidinediones
versus combined OCPs in inducing menstrual cyclicity,
reducing hyperandrogenism and hirsutism, and effects of
these medications on lipid levels and levels of cardiovascu-
lar risk markers.
1. Metformin
Metformin increases insulin sensitivity in the liver by: 1)
reducing gluconeogenic enzyme activities (PEPCK, FBPase,
glucose-6-phosphatase), 2) inhibiting hepatic uptake of lac-
tate and alanine, 3) increasing the conversion of pyruvate
to alanine, and 4) inhibiting glucose output. The cellular
consequence of these AMP-activated protein kinase
(AMPK)-mediated effects is alterations in the AMP/ATP
ratio. In addition, metformin increases peripheral glucose
uptake, decreases fatty acid oxidation and decreases glu-
cose absorption from the gut. Molecularly, metformin-
induced phosphorylation modulates the activities of both
a1 and a2 catalytic subunits of AMPK, resulting in
improved muscle glucose uptake in the presence of insulin.
Metformin-induced activation of AMPK may also augment
hepatic fatty acid oxidation and improve hepatic insulin
sensitivity. In human muscle biopsies, metformin’s effect is
transduced by phsophorylation of the a2 subunit threonine
residue 172, an effect maintained after discontinuation of
the medication. However, in mouse skeletal muscle cell
lines, metformin-induced phosphorylation of (primarily)
a1 Thr172 had no effect on AMP/ATP ratios. Thus,
the actual mechanism by which metformin activates
AMPK to sensitize target tissues to insulin, or even
whether the metformin effect requires AMPK in humans,
remains unproven [165].
Knowledge of the effects of insulin on free androgen
levels has prompted multiple trials of the efficacy of drugs
that increase insulin sensitivity or reduce insulin levels,
including metformin, in the treatment of PCOS [166-171].
Most of these studies targeted adult women with this dis-
order, often yielding promising results with respect to
resumption of menstrual cyclicity (in 50-60%), improved
percentage of ovulatory cycles, and fertility [reviewed in
[170]]. However, a recent large randomized study of more
than 600 women reported no improvement in fertility (as
assessed by live birth rates) with use of extended release
metformin in women with PCOS compared with clomi-
phene [172,173]. In adults with PCOS, increased abdom-
inal fat, decreased insulin sensitivity, and endothelial
dysfunction also contribute to increased cardiovascular
risk, and are associated with alterations in circulating
levels of adipocytokines; cardiovascular risk markers such
as endothelin-1, plasminogen activator-1 (PAI-1), and
lipoprotein (a); pro-inflammatory markers such as IL-1,
TNF-a, and CRP; and higher neutrophil counts [174-186].
The contribution of decreased insulin sensitivity to
increased cardiovascular risk makes a strong case for the
use of insulin sensitizers in PCOS in adults for benefits
beyond those associated with reproductive integrity.
Metformin has been used successfully in adult obese and
non-obese women to decrease levels of markers of cardio-
vascular risk in studies lasting an average of six months
[174,176,181,185-188].
Studies in adolescents with PCOS have been limited,
and data on the benefits of therapeutic intervention on
restoration of menstrual cyclicity less convincing than in
adults [174,189-191]. Longitudinal data are sparse regard-
ing the effects of decreased insulin sensitivity and
increased abdominal fat on long-term cardiovascular out-
comes in teenagers with PCOS, and few studies have
examined the relationship between cardiovascular risk fac-
tors and the use of metformin in this younger population.
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Recent work by Ibanez indicates that relatively lean girls
with hyperinsulinemic hyperandrogenism have a dyslipi-
demic profile, with high levels of triglycerides and other
atherogenic lipids [192]. Similarly, an increased prevalence
of the metabolic syndrome in adolescent girls with PCOS
compared with weight matched controls reported by Cov-
iello included evidence of abnormal lipid profiles [96].
A recent survey indicated that 30% of pediatric endocri-
nologists consider metformin appropriate treatment for
adolescents with PCOS, and 68% for obese adolescents
with PCOS [193]. The following sections briefly review
some adult and available adolescent data regarding efficacy
of insulin sensitizers in treating those with PCOS. The
bulk of available data in adolescents derives from studies
by Ibanez in relatively lean girls with a history of preco-
cious pubarche, hyperinsulinemic hyperandrogenism, and
post-pubertal features consistent with PCOS, studies
which remain to be replicated [55,189,192,194-197].
Androgen-lowering effects of metformin
In both lean and obese women with PCOS, metformin (i)
decreases insulin levels in association with decreases in
clinical indices of ovarian cytochrome P450c17 activity,
and (ii) increases SHBG levels, resulting in decreases in
free testosterone [60,61,63,64]. Long-term metformin ther-
apy may also decrease the activity of several other adrenal
steroidogenic pathway elements [198,199]. In addition,
metformin use is associated with increases levels of
IGFBP-1 (which may be a consequence of a reduction in
insulin levels), with the resultant decrease in IGF-1 bioa-
vailability possibly decreasing the stimulatory effects of
IGF-1 on ovarian steroidogenesis. However, Munir
demonstrated that modulation of human theca P450c17 in
vitro is transduced exclusively through insulin receptors,
rather than IGF-1 receptors [59], making less clear the
role of IGF-1 in governing thecal androgen production at
the whole body level.
Studies indicate that the degree to which metformin
therapy is effective in improving the androgenic and meta-
bolic profile in adolescents with PCOS may be related to
(i) dose used, particularly when metformin is used as
monotherapy, necessitating higher doses [191,200-202];
(ii) the agent with which metformin is combined, estro-
gen-progestin combination pills or anti-androgenic agents
such as flutamide, spironolactone, and cyproterone acetate
[115,116,203-210]; and (iii) the characteristics of the PCOS
patient being treated, whether obese or lean, hyperinsuli-
nemic, or normoinsulinemic [191,194,200,202,211,212].
We will consider each of these aspects individually:
Metformin monotherapy
A dose of 1.5-2 g per day appears necessary for clinical
effectiveness when metformin is used alone [201], the effi-
cacy dependent on the outcome measure chosen. Arsla-
nian reported decreased insulin sensitivity in fifteen obese
adolescents with PCOS in whom metformin therapy
(850 mg, twice daily) was associated with an improvement
in glucose tolerance and a decrease in testosterone levels
[191]. Six of the study subjects had simultaneous improve-
ments in menstrual cyclicity. Of note, these girls also had
significant decreases in BMI (mean decrease of 1.4 kg/m2)
over the three-month study period. In another study of
eleven obese girls with PCOS, metformin use was asso-
ciated with a downward trend in circulating testosterone
concentrations and a decrease in total cholesterol levels,
even after adjusting for weight loss [213]. Although a daily
metformin dose of 1.5 g (500 mg three times daily) was
effective in two of the eleven girls, nine required an
increase to 2.55 g (850 mg three times a day) after 8-10
weeks on the lower dose. Ninety percent of those treated
resumed regular menses, and in 39% of the follow up visits
in girls with regular menses, the cycles were ovulatory,
based on luteal phase (day 21) progesterone levels. The
proportion of girls resuming menses in this study was
higher than that observed in other studies of women with
PCOS receiving metformin, in which menstrual cyclicity
was restored in fewer than 50% overall [202,204,214,215].
A third uncontrolled study in 18 adolescent girls 15-18
years old similarly reported a reduction in levels of andro-
gens and resumption of menstrual cyclicity and ovulatory
cycles in all 16 girls who tolerated 1700 mg of metformin
daily. Girls in this study also had a reduction in BMI that
was maintained (along with regular and ovulatory men-
strual cycles) six months after the end of metformin treat-
ment [216]. The absence of a control group and
significant weight loss in subjects in these studies make
these data difficult to interpret in terms of metformin’s
efficacy independent of weight loss.
Similar results from a placebo-controlled study by
Bridger appear to confirm beneficial effects of metformin
monotherapy, at least in the short term [200]. In this
study, 22 obese adolescents with hyperinsulinemia and
PCOS were randomized to receive metformin (1.5 g per
day) or placebo for a twelve-week period. The group
receiving metformin had significant decreases in levels of
testosterone and increases in HDL-cholesterol, in the
absence of changes in insulin sensitivity or BMI. Because
insulin sensitivity did not significantly change with metfor-
min, a direct effect of metformin on androgen secretion
could not be ruled out. However, in an uncontrolled
study, Glueck reported that metformin therapy associated
with caloric restriction for 12 months in 35 adolescents
with PCOS was associated with a 4.4% decrease in weight,
as well as decreases in insulin, HOMA-IR (an index of
insulin sensitivity derived from fasting glucose and insulin
values), cholesterol and TG, and improved menstrual
function, with regular monthly cycles increasing from 22%
to 74% [217].
Lower doses of metformin have proven effective in
non-obese adolescents with PCOS. Ibanez and colleagues
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reported decreased ovarian hyperandrogenism, hyperin-
sulinemia, and hirsutism, as well as improved menstrual
cyclicity and lipid profiles in ten non-obese girls
with hyperinsulinemic hyperandrogenism treated with as
little as 1.25 g of metformin daily [197]. Leukocytosis,
another pro-inflammatory surrogate marker observed in
adolescents with hyperinsulinemic hyperandrogenism,
also normalizes with metformin monotherapy (vs. no
medication) in a randomized study design [174].
Metformin use is associated with gastrointestinal side
effects, which can be minimized by slow titration of the
medication to the desired dose over a one-month period.
In none of the studies presented above were severe
adverse effects with metformin observed; specifically, lactic
acidosis has not been reported in this population. Compli-
ance with the higher doses required in some teenagers
may be an obstacle to efficacy of metformin therapy, given
the potential for initial gastrointestinal side effects [200].
Extended-release metformin may be useful in such
instances.
Metformin (with or without anti-androgens) versus
estrogen-progestin combination pills)
E2-P combination pills are the treatment of first choice in
adolescents with PCOS (see above), particularly when
efforts at weight loss, including reduction in caloric intake
and increased physical activity, fail. Although exogenous
estrogen decreases free androgen levels by increasing
levels of SHBG and suppressing ovarian secretion of gona-
dal steroids (both estrogen and androgen), it neither
increases insulin sensitivity nor decreases inflammatory
mediators, adipose tissue or adipose-derived adipocyto-
kines, based on studies in adults [55,150,189,210,218,219],
and may cause an increase in lipids. In adolescent girls
with PCOS, Mastorakos demonstrated an increase in
levels of total, LDL- and HDL-associated cholesterol with
combined E2-P containing pills, and a tendency towards
increasing triglyceride levels with use of cyproterone acet-
ate-containing combination pills [150]. The same group
later reported increased IR after 12 months of both E2-P-
and cyproterone acetate-containing combination pills. The
later formulation also resulted in hyperinsulinemia [159].
An important question is whether metformin can
improve menstrual cyclicity and hirsutism scores in
PCOS without predisposing to the deleterious metabolic
effects attributed to use of combined oral contraceptive
agents. To answer this question, Hoeger randomized 43
adolescent girls with PCOS to either lifestyle interven-
tion, estrogen-progestin (ethinyl estradiol + desogestrel)
combination pills, metformin (1700 mg daily), or placebo
for a six-month period, and demonstrated that groups
randomized to lifestyle intervention and the combination
pills (but not metformin) had increases in SHBG levels
and reductions in free androgen index and in PAI-1
[133] despite only non-significant changes in weight in
all groups. Hirsutism scores did not change in any group.
Among girls not receiving OCPs, the frequency of
menses did not differ between groups; observed menses
were ovulatory 75% of the time in the metformin group,
as opposed to 60% of the time in the group receiving
combined pills and 50% of the time in the group rando-
mized to placebo. However, use of OCPs was associated
with a 14% increase in total cholesterol and 40% increase
in high-sensitivity CRP, whereas, these adverse metabolic
effects were not observed in the other groups, with the
metformin group demonstrating a 25% decrease in trigly-
ceride levels. Unlike the previous study, use of combined
pills did not result in hyperinsulinemia. Metformin use
was associated with a significant decrease in glucose
levels, but insulin levels did not change. These data sug-
gest that in obese adolescents with PCOS, OCPs and life-
style intervention have beneficial effects on androgen
levels. However, combination pills affect cardiovascular
risk markers adversely, while metformin has beneficial
effects on both lipids and glucose levels.
In contrast to these data, Allen found concurrent
decreases in both IR (measured by fasted baseline glucose/
insulin ratios and QUICKI derivation) and testosterone
levels in 35 obese PCOS girls randomized to either met-
formin or an OCP for six months [220]. Significantly, both
cohorts lost weight (mean BMI decrease of 1.5 kg/m2 in
the estrogen/progestin group and 1 kg/m2 in the metfor-
min group). The authors concluded that the two drugs
produced similar benefits for the cardinal features of
PCOS in adolescents.
Other data comparing combine OCPs and metformin
derive from Ibanez’ studies of non-obese hyperinsulinemic,
hyperandrogenic adolescents. In 32 such adolescents with
a mean age of 15 years and a BMI of 22 kg/m2, Ibanez and
de Zegher [189] found low baseline adiponectin levels and
increased abdominal fat. Over 3-9 months in a rando-
mized study design, E2-P (ethinyl estradiol + drospire-
none) combination pills further decreased adiponectin
levels while increasing both triglyceride levels and central
adiposity. Conversely, metformin (850 mg/day) in combi-
nation with low-dose flutamide (62.5 mg/day) reversed
these values towards normal, with a 4-kg mean decrease
in fat mass and a commensurate increase in lean mass.
These authors also observed that metformin attenuated
the pro-inflammatory state in young women with hyperin-
sulinemic hyperandrogenism, resulting in reductions in
IL-6 and CRP levels and neutrophil counts, whereas use of
E2-P combination pills aggravated the pro-inflammatory
state [174,189,221,222]. Whereas metformin alone did not
significantly reduce the free androgen index in obese ado-
lescents, the combination of metformin and flutamide was
as effective as E2-P combination pills in reducing the
hyperandrogenism associated with PCOS [133]. In addi-
tion, metformin was superior to E2-P in increasing insulin
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sensitivity, while decreasing dyslipidemia, anovulation,
body adiposity, and the pro-inflammatory state associated
with PCOS. It should be noted that the population of girls
studied by Ibanez and colleagues all had histories of preco-
cious adrenarche, perhaps suggestive of a unique sub-class
of PCOS patients.
Further studies are necessary to determine whether or
not metformin exerts beneficial effects beyond those of
combined OCPs alone, in the population of adolescent girls
with PCOS. Although definitive data from well-controlled
trials are lacking, reports suggest the cosmetic result
achieved with OCPs may be superior to that of metformin
in the treatment of hirsutism in adolescents with PCOS, at
least over a prolonged period. It remains to be definitively
determined whether the superior metabolic effects achieved
with metformin (in contrast with combination pills) in ado-
lescents with PCOS can be sustained and over what dura-
tion these effects persist. The re-emergence of phenotypic
and metabolic abnormalities following discontinuation of
medication is an important consideration, as recent data
suggest a loss of the benefits of metformin almost immedi-
ately after cessation of therapy [195,197,223]. This may be
of particular importance in adolescents in whom compli-
ance with medical therapy is often problematic.
Metformin in combination with estrogen-progestin
combination pills or anti-androgens
In adult women with PCOS, adding metformin to a com-
bination OCP decreases IR, as well as androgen levels.
However, the anticipated correction of deranged lipid pro-
files and abdominal obesity through metformin use
appears to be blunted [209,224,225]. In 36 adolescent
obese girls with PCOS randomized for six months to a
combined pill (ethinyl estradiol + drosperinone) with life-
style intervention and metformin (2000 mg daily) or to an
OCP with lifestyle intervention and placebo, weight reduc-
tions, increases in SHBG, and decreases in free androgen
index, and decreases in hirsutism scores occurred in both
groups, but did not differ between groups [133]. Total
cholesterol increased in both groups, but the metformin
group had greater increases in HDL. No changes in insulin
or glucose occurred in either group. Data from this study
suggest only modest metabolic benefits of adding metfor-
min to a regime of a combined pill with lifestyle interven-
tion in obese adolescents with PCOS.
In contrast, in 31 non-obese girls with hyperinsulinemic
hyperandrogenism (average age, 16 years), random assign-
ment to metformin-treated or not to a protocol consisting
of flutamide and ethinyl estradiol + drospirenone over a 3-
month period resulted in a decrease in IL-6 and an
increase in adiponectin levels in the group receiving met-
formin [222]. The authors examined the effects of ran-
domly withdrawing metformin use or not in 42 lean
young women (average age, 19 years), and again observed
beneficial effects of metformin. Similarly, addition of
metformin-flutamide led to normalization of leukocyte
and neutrophil counts in 41 young women (average age,
18 years), in whom prior use of ethinyl estradiol-drospire-
none had effected an increase in these inflammatory mar-
kers [174]. These women had improvements in insulin
sensitivity, dyslipidemia, ovulatory patterns, and adiposity
indices as a consequence of the addition of metformin-flu-
tamide to a regimen of OCP monotherapy. These data
suggest greater benefit when metformin is added to a
regime that includes combination pills in non-obese ado-
lescents and young women with PCOS.
The type of progesterone in the E2-P combination pill
used in conjunction with insulin sensitizers may also exert
variable effects on body composition. Ibanez and de
Zegher reported on 29 non-obese young women with
PCOS (~ 20 years of age) receiving metformin+flutamide
combination therapy. When switched from a combination
pill with gestodene to one containing drospirenone, these
patients exhibited decreased abdominal fat mass and
increased lean mass without changes in overall body
weight [221]. Of note, both gestodene and drospirenone
are newer synthetic progestins. As a class, progestins bind
weakly to the androgen receptor, resulting in variable
androgenic effects. Whereas gestodene has minimal
androgenic properties, drospirenone exerts no androgenic
effects, and in fact antagonizes the androgen receptor after
binding (although in doses higher than those used in com-
bination pills). Drospirenone also has anti-mineralocorti-
coid effects and is therefore thought to minimize the
water retention and breast tenderness associated with
combination pills.
Anti-androgens such as spironolactone, cyproterone
acetate, and flutamide are commonly administered to
address the androgen excess features of PCOS. The anti-
androgenic effects of flutamide, a non-steroidal androgen
receptor antagonist, appear superior to those of spirono-
lactone or cyproterone acetate (the latter not available in
the U.S. at present) [203,226]. The combination of metfor-
min with anti-androgens appears promising based on a
handful of recent studies in lean [206] and obese [205]
young adult women with PCOS, as well as in lean adoles-
cent girls with hyperinsulinemic hyperandrogenism
[174,189,190]. This combination effectively decreases
abdominal obesity and levels of inflammatory markers in
these limited studies. When used alone and in high doses,
flutamide can be hepatotoxic; however, flutamide has a
good safety profile when used in polytherapy and in lower
dosages [116,227]. A combination of low-dose flutamide
(62.5 mg) and metformin (850 mg) appears both safe and
effective in adolescents and young women, in durations
ranging from 3-54 months (mean, 19 months), with pre-
servation of normal liver function [228]. Thus, data from
the Ibanez group suggest that low-dose polytherapy pro-
vides both an enhanced safety profile and an expanded
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spectrum of clinical benefit, when contrasted with high-
dose monotherapy, owing to the metabolic corrections
exerted by the metformin [190]. Lastly, some have
endorsed the use of finasteride, a 5-a reductase inhibitor
that blocks conversion of testosterone to its dihydrotestos-
terone metabolite in skin target tissue, to ameliorate the
dermatologic effects of androgen excess in adults. This
medication remains off-label for adolescents, alone or in
combination with metformin or other insulin sensitizers.
It is mandatory to exclude pregnancy in those adolescents
whose treatment regimen includes the use of anti-andro-
gens, due to their potential for precluding proper viriliza-
tion of male fetuses. Even more important is the need to
emphasize ongoing use of contraception, given the
increase in ovulatory rates as a result of metformin use.
Metformin use in obese versus lean, and hyperinsulinemic
versus normoinsulinemic PCOS
Silfen [100] observed that lean adolescents with PCOS
had lower insulin levels, increased insulin sensitivity, and
a more favorable lipid profile than did obese adolescents
with PCOS. Conversely, levels of adrenal androgens were
higher in the lean PCOS subjects. Given these differ-
ences, one might anticipate differences in individual
responses to metformin as a function of body composi-
tion. However, all studies to date report beneficial effects
of metformin in lean as well as obese adolescents with
PCOS [55,191,195,213].
Regrettably, there is a paucity of data regarding the use
of metformin in hyperinsulinemic versus normoinsuline-
mic adolescents with PCOS, and it remains unclear
whether metformin use should be restricted to adolescents
with PCOS (both obese and lean) with biochemical or
phenotypic (i.e., acanthosis nigricans) evidence of hyperin-
sulinemia. Ibanez and colleagues define hyperinsulinemia
as a peak insulin of > 150 μU/mL during a 2-hr oral glu-
cose tolerance test and/or mean serum insulin levels of
> 84 μIU/mL during standard oral glucose tolerance test-
ing [54,55,104,189,190,192,195,206,221-223,229-232].
Vuguin [233] and Silfen [234] demonstrated good correla-
tion between fasting glucose:insulin ratios of < 7 mg/10-4
IU and IVGTT measures of IR in adolescents with prema-
ture adrenarche, substantially greater than the figure
determined for IR associated with adult PCOS (approxi-
mately, 4.5 mg/10-4 IU) [235].
Significant effects of metformin on hirsutism scores
and ovulation were found in lean, hyperinsulinemic
women with PCOS, and a decrease in DHEA-S levels in
lean PCOS, regardless of insulin levels [211]. In over-
weight and obese women with PCOS, significant effects
were observed on waist-hip ratio in the normoinsuline-
mic overweight women, and on menstrual cyclicity in
normoinsulinemic obese women. Although these data
suggest beneficial effects of metformin on body compo-
sition and menstrual function in normoinsulinemic
overweight and obese adults, it is not known whether
these data can be extrapolated to adolescents, and in
particular to lean normoinsulinemic adolescents. Further
studies will be necessary to address these specific ques-
tions in adolescents with PCOS. In conclusion, use of
low-dose polytherapy may be superior to high-dose
monotherapy with respect to efficacy and safety profile;
however, further studies in adolescents with PCOS are
necessary before definitive recommendations can be
developed.
Prevention of PCOS with metformin (earlier intervention)
Girls at higher risk to develop PCOS, such as those with
low birth weight and precocious pubarche [196,236],
have a slowing of progression of endocrine-metabolic
perturbations associated with PCOS when metformin is
started during either the pre-pubertal or early post-
menarchal period [223,237]. This observation has been
exploited to propose a benefit to early intervention in
high-risk groups predisposed to PCOS. Of greater con-
cern are data suggesting that these benefits are lost
almost immediately following discontinuation of metfor-
min [195,197,223].
2. Thiazolidenediones
Thiazolidenediones act as insulin sensitizers through their
activation of the nuclear receptor PPAR-g, leading to
increased production of insulin-sensitive adipocytes and
increased glucose uptake in these cells, increased secretion
of adiponectin, and decreased secretion of pro-inflamma-
tory cytokines. Recent data in adult women with PCOS
suggest that thiazolidinediones exert additional benefit
with respect to hyperandrogenism, IR, anovulation, and
inflammatory mediator levels, in both lean and obese
women with PCOS [212,238-242]. These benefits are
observed despite increases in weight, BMI, and waist to
hip ratio in those treated [239]. Seto-Young and colleagues
have proposed that the effects of thiazolideindiones may
be independent of the effects on insulin secretion [243].
These authors reported that PPARg-agonists stimulate
IGFBP-1 and progesterone production, directly decrease
estrogen and testosterone secretion, and concurrently
antagonize the insulin-induced enhancement of estrogen
and testosterone secretion in cultured human ovarian
cells. The thiazolidenedione, pioglitazone, has been shown
to ameliorate the signs and symptoms of PCOS in a cohort
of women who failed a previous trial of metformin [244].
These medications have not been rigorously studied in
adolescents, in either traditional states of IR or in late ado-
lescent girls with unambiguous PCOS; thus, they remain
“off label” for use in this age group. Despite proven effi-
cacy in mitigating both IR and androgen excess while
restoring menstrual cyclicity in adult women with PCOS
[245,246], FDA concerns led to the removal of the van-
guard thiazolidenedione, troglitazone, from the market.
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Concerns regarding potential adverse cardiovascular
events in T2DM patients taking thaizolidenediones (e.g.,
Avandia, [rosiglitazone]) resulted in the recent addition of
a black box warning to the package inserts for that agent,
thus reinforcing the need for caution when considering
use of this class of medication, in both adolescents and
women with PCOS. Concerns about hepatotoxicity and
peripheral lipogenetic effects must be addressed before the
use of these medications in adolescent girls can be
endorsed without reservation [241,243]. Of note, one case
report has indicated efficacy of pioglitazone, but not met-
formin, in ameliorating insulin resistance, hyperinsuline-
mia, and hyperandrogenism, and in resumption of menses
in two sisters with Dunnigan-type familial partial lipody-
strophy [247].
Conclusion
PCOS is a multi-phenotypic disorder characterized by
androgen excess and menstrual acyclicity, with demon-
strable biochemical aberrations during pubertal matura-
tion, and clinical manifestations shortly after pubertal
completion. A variety of therapies may rectify both the
biochemical derangements and clinical features (Table 1)
of PCOS, and many patients are treated with polytherapy
to address the multiple facets of the syndrome. Women
with PCOS have abnormalities of insulin secretion and
action, and underlying IR has been proposed to be funda-
mental to the development of ovarian hyperandrogenism.
Application of therapies to diminish IR and consequent
hyperinsulinemia has gained increasing support as first-
line therapy. As listed in Table 2, arguments can be made
in support of and against the use of insulin sensitizers in
the treatment of adolescent PCOS. Studies demonstrating
long-term efficacy and safety of metformin and the thiazo-
lidenediones in the adolescent age group are lacking, hav-
ing been chiefly limited to adult women with PCOS,
particularly those with impaired glucose tolerance and
overt T2DM [248]: these are clearly essential in order to
promote their use as therapeutic options for adolescents
with PCOS. The paucity of data on the effects of these
modalities in the treatment of adolescent PCOS highlights
the need for well-designed, controlled studies to optimize
treatment algorithms for this disorder in the late teen and
young adult. The variability of phenotypic expression
within the syndrome further confounds advocacy of a sin-
gle treatment regimen, the determination of which
requires individualization to address the specific present-
ing complaint(s) of the adolescent patient. Additionally,
future individualization of treatment options will rely
increasingly on pharmacogenomic models that evaluate
putative genetic determinants of metformin response (as
described in adult type 2 DM patients) [249-252], to
improve prediction of therapeutic efficacy. To date, large-
scale studies targeting the prevalence of specific metfor-
min response elements have not been undertaken in either
adolescent or adult PCOS populations. Finally, when treat-
ing teenagers, a comprehensive approach is imperative,
one that considers important ancillary issues such as pre-
vention of pregnancy in those who are sexually active, as
well as the need to stress lifestyle counseling for those
with significant obesity and/or IR. Although beyond the
scope of this review, the use of cosmetic measures to com-
bat hirsutism and dermatological approaches to address
acne are common practice and serve as useful adjuncts to
the specific medical therapies for PCOS. Other cosmetic
concerns, particularly regarding the increased BMI, are of
paramount importance in this adolescent patient cohort,
with serious negative effect on an affected teenager’s qual-
ity of life [253,254]. The insufficiency of validated data
concerning the use of the insulin sensitizers in adolescent
PCOS justifies the continued designation of these medica-
tions as “off label” in this age group, which thus cannot be
recommended as first-line therapy at the present time.
Summary
Background
1. PCOS, a heterogeneous disorder characterized by cys-
tic ovarian morphology, androgen excess, and/or irregu-
lar periods, emerges during or shortly after puberty.
2. Insulin resistance and consequent hyperinsulinemia
are highly prevalent and facilitate the formation of
excess androgen.
Lifestyle Changes
1. Lifestyle changes involving behavioral, dietary, and
exercise regimens should be considered as first line
therapy for weight reduction and improvement of insu-
lin levels in obese adolescents with PCOS.
OCPs
1. OCPs, the traditional treatment option for both adult
and adolescent women with PCOS not wishing to
become pregnant, restore menstrual cyclicity and reduce
signs of androgen excess without improving IR.
2. Studies on the risk-benefit profiles for different
OCPs provide equivocal results with regard to hirsutism,
acne, and menstrual dysfunction, and lack sufficient data
on their efficacy and safety in the adolescent population.
3. Cardiovascular risk markers, often high in the
PCOS population, may be increased by OCPs.
Metformin
1. Several, although not all, studies of adult women with
PCOS treated with metformin demonstrate promising
results for resumption of menstrual cyclicity and ovula-
tion, restoration of fertility, improved insulin dynamics,
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adipocytokine and inflammatory mediator profiles, and
cardiovascular indices.
2. The benefits to adults with PCOS in improving hir-
sutism scores, menstrual cyclicity, and metabolic status
depends on whether metformin is used as monotherapy
or in combination with anti-androgen and/or OCP, as
well as the insulin sensitivity status of the patient.
3. In adolescents with PCOS, little is known about the
safety and efficacy of metformin, either in mono- or
combination therapy.
Other
1. Thiazolidinediones may provide reproductive, meta-
bolic, and cardiovascular function benefits to adult
women with PCOS in whom previous metformin ther-
apy failed.
2. Thiazolidinediones remain off-label in adolescents,
due to lack of evidence on efficacy and safety.
Acknowledgements
The authors would like to thank the Pediatric Endocrine Society (PES) Drug
and Therapeutics Committee for its careful review of the manuscript and
constructive comments. We would also like to acknowledge the Board of
Directors of the PES for their review and endorsement of this manuscript.
Author details
1Division of Pediatric Endocrinology, Cedars-Sinai Medical Center, David
Geffen-UCLA School of Medicine 8700 Beverly Blvd., Rm 4220, Los Angeles,
CA 90048, USA. 2Division of Pediatric Endocrinology, Alberta Children’s
Hospital, University of Calgary, 2888 Hospital Drive NW, Calgary, Alberta T2N
4Z6, Canada. 3Divisions of Adolescent Medicine and Endocrinology,
Children’s Hospital and Harvard Medical School, 300 Longwood Avenue, 333
Longwood-6, Boston, MA 02115, USA. 4Pediatric Endocrine Unit, Mass
General Hospital for Children and Harvard Medical School, 55 Fruit Street,
Boston, MA 02114, USA.
Authors’ contributions
DHG participated in the planning, implementation, writing, review and
editing of the manuscript. DP participated in the planning, implementation,
writing, review and editing of the manuscript. CMG participated in the
review and editing of the manuscript. MM participated in the conception,
planning, implementation, writing, review and editing of the manuscript. All
authors have read and approved the final manuscript.
Competing interests
The authors have no competing financial or other interests to declare in
relation to this manuscript.
Received: 27 July 2011 Accepted: 26 August 2011
Published: 26 August 2011
References
1. Asuncion M, Calvo RM, San Millan JL, et al: A prospective study of the
prevalence of the polycystic ovary syndrome in unselected Caucasian
women from Spain. J Clin Endocrinol Metab 2000, 85(7):2434-8.
2. Azziz R, Woods KS, Reyna R, et al: The prevalence and features of the
polycystic ovary syndrome in an unselected population. J Clin Endocrinol
Metab 2004, 89(6):2745-9.
3. Goodarzi MO, Quinones MJ, Azziz R, et al: Polycystic ovary syndrome in
Mexican-Americans: prevalence and association with the severity of
insulin resistance. Fertil Steril 2005, 84(3):766-9.
4. Rotterdam E: Revised 2003 consensus on diagnostic criteria and long-
term health risks related to polycystic ovary syndrome. Fertility and
Sterility 2004, 81(1):19-25.
5. Yildiz BO, Azziz R: Ovarian and adipose tissue dysfunction in polycystic
ovary syndrome: report of the 4th special scientific meeting of the
Androgen Excess and PCOS Society. Fertil Steril 2010, 94(2):690-3.
6. Gilling-Smith C, Story H, Rogers V, et al: Evidence for a primary
abnormality of thecal cell steroidogenesis in the polycystic ovary
syndrome. Clin Endocrinol (Oxf) 1997, 47(1):93-9.
7. Nelson VL, Legro RS, Strauss JF, et al: Augmented androgen production is
a stable steroidogenic phenotype of propagated theca cells from
polycystic ovaries. Mol Endocrinol 1999, 13(6):946-57.
8. Franks S, Stark J, Hardy K: Follicle dynamics and anovulation in polycystic
ovary syndrome. Hum Reprod Update 2008, 14(4):367-78.
9. Huang A, Brennan K, Azziz R: Prevalence of hyperandrogenemia in the
polycystic ovary syndrome diagnosed by the National Institutes of
Health 1990 criteria. Fertil Steril 2010, 93(6):1938-41.
Table 2 Pros and cons of insulin sensitizer therapy in PCOS
PROS CONS
Reduces insulin resistance and addresses an important component of
the pathophysiology of PCOS
Useful for treating hyperglycemia in patients with PCOS-associated
type 2 DM
Insulin-sensitizing effect may not persist after discontinuing medication
Metformin may cause weight reduction and is associated with
improvement in lipid profile
Weight reduction is minor with metformin; TZDs may cause weight gain
and peripheral lipogenesis
Cosmetic improvements with insulin sensitizers may be less marked than
with E2-P combination pills
Insulin sensitizers may induce ovulation with risk of unwanted pregnancy
unless used with contraception
An option in patients with Factor V Leiden mutations and other risk
factors for coagulopathy in whom E2-P combination pills may be
contraindicated
Potential for use in adolescents with lean PCOS in whom lifestyle
modification is likely to be ineffective
Lean PCOS responds well to conventional E2-P combination pills in
conjunction with anti-androgen medications
Excellent safety profile for metformin, with few side effects reported Insulin sensitizers are potential teratogens Select patients may require
frequent monitoring of liver and renal function TZDs have been associated
with adverse cardiovascular events in adult patients
Insufficient studies of efficacy and long term safety of insulin sensitizers in
adolescents
Geller et al. International Journal of Pediatric Endocrinology 2011, 2011:9
http://www.ijpeonline.com/content/2011/1/9
Page 13 of 19
10. Kiddy DS, Sharp PS, White DM, et al: Differences in clinical and endocrine
features between obese and non-obese subjects with polycystic ovary
syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf)
1990, 32(2):213-20.
11. Ehrmann DA, Liljenquist DR, Kasza K, et al: Prevalence and predictors of
the metabolic syndrome in women with polycystic ovary syndrome. J
Clin Endocrinol Metab 2006, 91(1):48-53.
12. Carmina E, Lobo RA: Use of fasting blood to assess the prevalence of
insulin resistance in women with polycystic ovary syndrome. Fertil Steril
2004, 82(3):661-5.
13. DeUgarte CM, Bartolucci AA, Azziz R: Prevalence of insulin resistance in
the polycystic ovary syndrome using the homeostasis model
assessment. Fertil Steril 2005, 83(5):1454-60.
14. Yildiz BO, Knochenhauer ES, Azziz R: Impact of obesity on the risk for
polycystic ovary syndrome. J Clin Endocrinol Metab 2008, 93(1):162-8.
15. Azziz R: Controversy in clinical endocrinology: diagnosis of polycystic
ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol
Metab 2006, 91(3):781-5.
16. Dunaif A: Insulin resistance and the polycystic ovary syndrome:
mechanism and implications for pathogenesis. Endocr Rev 1997,
18(6):774-800.
17. Azziz R, Marin C, Hoq L, et al: Health care-related economic burden of the
polycystic ovary syndrome during the reproductive life span. J Clin
Endocrinol Metab 2005, 90:4650-4658.
18. Talbott EO, Zborowski JV, Rager JR, et al: Polycystic ovarian syndrome
(PCOS): a significant contributor to the overall burden of type 2
diabetes in women. J Womens Health (Larchmt) 2007, 16(2):191-7.
19. Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, et al: Prevalence and
characteristics of the polycystic ovary syndrome in overweight and
obese women. Arch Intern Med 2006, 166(19):2081-6.
20. Ehrmann DA, Barnes RB, Rosenfield RL, et al: Prevalence of impaired
glucose tolerance and diabetes in women with polycystic ovary
syndrome. Diabetes Care 1999, 22(1):141-6.
21. Ehrmann DA, Kasza K, Azziz R, et al: Effects of race and family history of
type 2 diabetes on metabolic status of women with polycystic ovary
syndrome. J Clin Endocrinol Metab 2005, 90(1):66-71.
22. Legro RS, Kunselman AR, Dodson WC, et al: Prevalence and predictors of
risk for type 2 diabetes mellitus and impaired glucose tolerance in
polycystic ovary syndrome: a prospective, controlled study in 254
affected women. J Clin Endocrinol Metab 1999, 84(1):165-9.
23. Moran LJ, Misso ML, Wild RA, et al: Impaired glucose tolerance, type 2
diabetes and metabolic syndrome in polycystic ovary syndrome: a
systematic review and meta-analysis. Hum Reprod Update 2010,
16(4):347-63.
24. Wild RA, Carmina E, Diamanti-Kandarakis E, et al: Assessment of
cardiovascular risk and prevention of cardiovascular disease in women
with the polycystic ovary syndrome: a consensus statement by the
Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J
Clin Endocrinol Metab 2010, 95(5):2038-49.
25. Salley KE, Wickham EP, Cheang KI, et al: Glucose intolerance in polycystic
ovary syndrome–a position statement of the Androgen Excess Society. J
Clin Endocrinol Metab 2007, 92(12):4546-56.
26. Achard EC, Thiers J: Le virilisme pilaire et son association a l’insuffisance
glycolitique (diabète des femmes à barbe). Bulletin Acad Nat Med, Paris
1921, 86:51-85.
27. Stein I, Leventhal M: Amenorrhea associated with bilateral polycystic
ovaries. Am J Obstet Gynecol 1935, 29:181-91.
28. Barbieri RL, Ryan KJ: Hyperandrogenism, insulin resistance, and
acanthosis nigricans syndrome: a common endocrinopathy with distinct
pathophysiologic features. Am J Obstet Gynecol 1983, 147(1):90-101.
29. Kahn CR, Flier JS, Bar RS, et al: The syndromes of insulin resistance and
acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med
1976, 294(14):739-45.
30. O’Rahilly S, Choi WH, Patel P, et al: Detection of mutations in insulin-
receptor gene in NIDDM patients by analysis of single-stranded
conformation polymorphisms. Diabetes 1991, 40(6):777-82.
31. Taylor SI, Cama A, Accili D, et al: Mutations in the insulin receptor gene.
Endocr Rev 1992, 13(3):566-95.
32. Flier JS, Kahn CR, Roth J, et al: Antibodies that impair insulin receptor
binding in an unusual diabetic syndrome with severe insulin resistance.
Science 1975, 190(4209):63-5.
33. Flier JS, Eastman RC, Minaker KL, et al: Acanthosis nigricans in obese
women with hyperandrogenism. Characterization of an insulin-resistant
state distinct from the type A and B syndromes. Diabetes 1985,
34(2):101-7.
34. Burghen GA, Givens JR, Kitabchi AE: Correlation of hyperandrogenism
with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab
1980, 50(1):113-6.
35. Franks S: Polycystic ovary syndrome. N Engl J Med 1995, 333(13):853-61.
36. Holte J: Disturbances in insulin secretion and sensitivity in women with
the polycystic ovary syndrome. Baillieres Clin Endocrinol Metab 1996,
10(2):221-47.
37. Toprak S, Yonem A, Cakir B, et al: Insulin resistance in nonobese patients
with polycystic ovary syndrome. Horm Res 2001, 55(2):65-70.
38. Homburg R, Lambalk CB: Polycystic ovary syndrome in adolescence–a
therapeutic conundrum. Hum Reprod 2004, 19(5):1039-42.
39. Acien P, Quereda F, Matallin P, et al: Insulin, androgens, and obesity in
women with and without polycystic ovary syndrome: a heterogeneous
group of disorders. Fertil Steril 1999, 72(1):32-40.
40. Ciampelli M, Fulghesu AM, Cucinelli F, et al: Impact of insulin and body
mass index on metabolic and endocrine variables in polycystic ovary
syndrome. Metabolism 1999, 48(2):167-72.
41. Dunaif A, Segal KR, Futterweit W, et al: Profound peripheral insulin
resistance, independent of obesity, in polycystic ovary syndrome.
Diabetes 1989, 38(9):1165-74.
42. Chang RJ, Nakamura RM, Judd HL, et al: Insulin resistance in nonobese
patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983,
57(2):356-9.
43. Dunaif A, Hoffman AR, Scully RE, et al: Clinical, biochemical, and ovarian
morphologic features in women with acanthosis nigricans and
masculinization. Obstet Gynecol 1985, 66(4):545-52.
44. Mather KJ, Kwan F, Corenblum B: Hyperinsulinemia in polycystic ovary
syndrome correlates with increased cardiovascular risk independent of
obesity. Fertil Steril 2000, 73(1):150-6.
45. Ehrmann DA, Sturis J, Byrne MM, et al: Insulin secretory defects in
polycystic ovary syndrome. Relationship to insulin sensitivity and family
history of non-insulin-dependent diabetes mellitus. J Clin Invest 1995,
96(1):520-7.
46. Dunaif A, Finegood DT: Beta-cell dysfunction independent of obesity and
glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol
Metab 1996, 81(3):942-7.
47. Vrbikova J, Cibula D, Dvorakova K, et al: Insulin sensitivity in women with
polycystic ovary syndrome. J Clin Endocrinol Metab 2004, 89(6):2942-2945.
48. Morales AJ, Laughlin GA, Butzow T, et al: Insulin, somatotropic, and
luteinizing hormone axes in lean and obese women with polycystic
ovary syndrome: common and distinct features. J Clin Endocrinol Metab
1996, 81(8):2854-64.
49. Ovesen P, Moller J, Ingerslev HJ, et al: Normal basal and insulin-stimulated
fuel metabolism in lean women with the polycystic ovary syndrome. J
Clin Endocrinol Metab 1993, 77(6):1636-40.
50. Diamanti-Kandarakis E, Kouli C, Alexandraki K, et al: Failure of mathematical
indices to accurately assess insulin resistance in lean, overweight, or
obese women with polycystic ovary syndrome. J Clin Endocrinol Metab
2004, 89(3):1273-6.
51. Palmert MR, Gordon CM, Kartashov AI, et al: Screening for abnormal
glucose tolerance in adolescents with polycystic ovary syndrome. J Clin
Endocrinol Metab 2002, 87(3):1017-23.
52. Cutfield WS, Jefferies CA, Jackson WE, et al: Evaluation of HOMA and
QUICKI as measures of insulin sensitivity in prepubertal children. Pediatr
Diabetes 2003, 4(3):119-25.
53. Kirchengast S, Huber J: Body composition characteristics and body fat
distribution in lean women with polycystic ovary syndrome. Hum Reprod
2001, 16(6):1255-60.
54. Ibanez L, Ong K, de Zegher F, et al: Fat distribution in non-obese girls
with and without precocious pubarche: central adiposity related to
insulinaemia and androgenaemia from prepuberty to postmenarche.
Clin Endocrinol (Oxf) 2003, 58(3):372-9.
55. Ibanez L, De Zegher F: Flutamide-metformin therapy to reduce fat mass
in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents
and in women on third-generation oral contraception. J Clin Endocrinol
Metab 2003, 88(10):4720-4.
Geller et al. International Journal of Pediatric Endocrinology 2011, 2011:9
http://www.ijpeonline.com/content/2011/1/9
Page 14 of 19
56. Puder JJ, Varga S, Kraenzlin M, et al: Central fat excess in polycystic ovary
syndrome: relation to low-grade inflammation and insulin resistance. J
Clin Endocrinol Metab 2005, 90(11):6014-21.
57. Morin-Papunen LC, Vauhkonen I, Koivunen RM, et al: Insulin sensitivity,
insulin secretion, and metabolic and hormonal parameters in healthy
women and women with polycystic ovarian syndrome. Hum Reprod
2000, 15(6):1266-74.
58. Nestler JE, Jakubowicz DJ, Falcon de Vargas A, et al: Insulin stimulates
testosterone biosynthesis by human thecal cells from women with
polycystic ovary syndrome by activating its own receptor and using
inositolglycan mediators as the signal transduction system. J Clin
Endocrinol Metab 1998, 83(6):2001-2005.
59. Munir I, Yen HW, Geller DH, et al: Insulin augmentation of 17alpha-
hydroxylase activity is mediated by phosphatidyl inositol 3-kinase but
not extracellular signal-regulated kinase-1/2 in human ovarian theca
cells. Endocrinology 2004, 145(1):175-83.
60. Nestler JE, Jakubowicz DJ: Decreases in ovarian cytochrome P450c17
alpha activity and serum free testosterone after reduction of insulin
secretion in polycystic ovary syndrome. N Engl J Med 1996,
335(9):617-23.
61. Nestler JE, Jakubowicz DJ: Lean women with polycystic ovary syndrome
respond to insulin reduction with decreases in ovarian P450c17 alpha
activity and serum androgens. J Clin Endocrinol Metab 1997, 82(12):4075-9.
62. Zhang LH, Rodriguez H, Ohno S, et al: Serine phosphorylation of human
P450c17 increases 17,20-lyase activity: implications for adrenarche and
the polycystic ovary syndrome. Proc Natl Acad Sci U S A 1995,
92(23):10619-23.
63. Plymate SR, Matej LA, Jones RE, et al: Inhibition of sex hormone-binding
globulin production in the human hepatoma (Hep G2) cell line by
insulin and prolactin. J Clin Endocrinol Metab 1988, 67(3):460-4.
64. Nestler JE, Powers LP, Matt DW, et al: A direct effect of hyperinsulinemia
on serum sex hormone-binding globulin levels in obese women with
polycystic ovary syndrome. J Clin Endocrinol Metab 1991, 72(1):83-9.
65. Blank SK, McCartney CR, Marshall JC: The origins and sequelae of
abnormal neuroendocrine function in polycystic ovary syndrome. Hum
Reprod Update 2006, 12(4):351-61.
66. Chhabra S, McCartney CR, Yoo RY, et al: Progesterone inhibition of the
hypothalamic gonadotropin-releasing hormone pulse generator:
evidence for varied effects in hyperandrogenemic adolescent girls. J Clin
Endocrinol Metab 2005, 90(5):2810-5.
67. Marshall JC, Eagleson CA: Neuroendocrine aspects of polycystic ovary
syndrome. Endocrinol Metab Clin North Am 1999, 28(2):295-324.
68. Mehta RV, Patel KS, Coffler MS, et al: Luteinizing hormone secretion is not
influenced by insulin infusion in women with polycystic ovary syndrome
despite improved insulin sensitivity during pioglitazone treatment. J Clin
Endocrinol Metab 2005, 90(4):2136-41.
69. Pagan YLea: Inverse relationship between luteinizing hormone and body
mass index in polycystic ovarian syndrome: investigation of
hypothalamic and pituitary contributions. J Clin Endocrinol Metab 2006,
91:1309-16.
70. Srouji SSea: Pharmacokinetic factors contribute to the inverse
relationship between luteinizing hormone and body mass index in
polycystic ovarian syndrome. J Clin Endocrinol Metab 2007, 92:1347-52.
71. Hall JE, Taylor AE, Hayes RJ, et al: Insights into hypothalamic-pituitary
dysfunction in polycystic ovary syndrome. J Endocrinol Invest 1998,
21:602-11.
72. Taylor AEea: Determinants of abnormal gonadotropin secretion in
clinically defined women with polycystic ovary syndrome. J Clin
Endocrinol Metab 1997, 82:2248-56.
73. Vink JM, Sadrzadeh S, Lambalk CB, et al: Heritability of polycystic ovary
syndrome in a Dutch twin-family study. J Clin Endocrinol Metab 2006,
91(6):2100-4.
74. Goodarzi MO: Looking for polycystic ovary syndrome genes: rational and
best strategy. Semin Reprod Med 2008, 26(1):5-13.
75. Gaasenbeek M, Powell BL, Sovio U, et al: Large-scale analysis of the
relationship between CYP11A promoter variation, polycystic ovarian
syndrome, and serum testosterone. J Clin Endocrinol Metab 2004,
89(5):2408-13.
76. Goodarzi MO, Jones MR, Antoine HJ, et al: Nonreplication of the type 5
17beta-hydroxysteroid dehydrogenase gene association with polycystic
ovary syndrome. J Clin Endocrinol Metab 2008, 93(1):300-3.
77. Powell BL, Haddad L, Bennett A, et al: Analysis of multiple data sets
reveals no association between the insulin gene variable number
tandem repeat element and polycystic ovary syndrome or related traits.
J Clin Endocrinol Metab 2005, 90(5):2988-93.
78. Urbanek M, Woodroffe A, Ewens KG, et al: Candidate gene region for
polycystic ovary syndrome on chromosome 19p13.2. J Clin Endocrinol
Metab 2005, 90(12):6623-9.
79. Jones MR, Mathur R, Cui J, et al: Independent confirmation of association
between metabolic phenotypes of polycystic ovary syndrome and
variation in the type 6 17beta-hydroxysteroid dehydrogenase gene. J
Clin Endocrinol Metab 2009, 94(12):5034-8.
80. Ewens KGea: Family-based analysis of candidate genes for polycystic
ovary syndrome. J Clin Endocrinol Metab 2010, 95:2306-15.
81. Govind A, Obhrai MS, Clayton RN: Polycystic ovaries are inherited as an
autosomal dominant trait: analysis of 29 polycystic ovary syndrome and
10 control families. J Clin Endocrinol Metab 1999, 84(1):38-43.
82. Legro RS, Driscoll D, Strauss JF, et al: Evidence for a genetic basis for
hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S
A 1998, 95(25):14956-60.
83. Lunde O, Magnus P, Sandvik L, et al: Familial clustering in the polycystic
ovarian syndrome. Gynecol Obstet Invest 1989, 28(1):23-30.
84. Kahsar-Miller MD, Nixon C, Boots LR, et al: Prevalence of polycystic ovary
syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil
Steril 2001, 75(1):53-8.
85. Sir-Petermann T, Angel B, Maliqueo M, et al: Prevalence of Type II diabetes
mellitus and insulin resistance in parents of women with polycystic
ovary syndrome. Diabetologia 2002, 45(7):959-64.
86. Sam S, Legro RS, Essah PA, et al: Evidence for metabolic and reproductive
phenotypes in mothers of women with polycystic ovary syndrome. Proc
Natl Acad Sci U S A 2006, 103(18):7030-5.
87. Sam S, Legro RS, Bentley-Lewis R, et al: Dyslipidemia and metabolic
syndrome in the sisters of women with polycystic ovary syndrome. J Clin
Endocrinol Metab 2005, 90(8):4797-802.
88. Colilla S, Cox NJ, Ehrmann DA: Heritability of insulin secretion and insulin
action in women with polycystic ovary syndrome and their first degree
relatives. J Clin Endocrinol Metab 2001, 86(5):2027-31.
89. Legro RS, Kunselman AR, Demers L, et al: Elevated
dehydroepiandrosterone sulfate levels as the reproductive phenotype in
the brothers of women with polycystic ovary syndrome. J Clin Endocrinol
Metab 2002, 87(5):2134-8.
90. Kaushal R, Parchure N, Bano G, et al: Insulin resistance and endothelial
dysfunction in the brothers of Indian subcontinent Asian women with
polycystic ovaries. Clin Endocrinol (Oxf) 2004, 60(3):322-8.
91. Coviello AD, Sam S, Legro RS, et al: High prevalence of metabolic
syndrome in first-degree male relatives of women with polycystic ovary
syndrome is related to high rates of obesity. J Clin Endocrinol Metab 2009,
94(11):4361-6.
92. Sir-Petermann T, Codner E, Perez V, et al: Metabolic and reproductive
features before and during puberty in daughters of women with
polycystic ovary syndrome. J Clin Endocrinol Metab 2009, 94(6):1923-30.
93. Sir-Petermann T, Maliqueo M, Codner E, et al: Early metabolic
derangements in daughters of women with polycystic ovary syndrome.
J Clin Endocrinol Metab 2007, 92(12):4637-42.
94. Kent SC, Gnatuk CL, Kunselman AR, et al: Hyperandrogenism and
hyperinsulinism in children of women with polycystic ovary syndrome: a
controlled study. J Clin Endocrinol Metab 2008, 93(5):1662-9.
95. Francis GL, Getts A, McPherson JC: Preliminary results suggesting
exaggerated ovarian androgen production early in the course of
polycystic ovary syndrome. J Adolesc Health Care 1990, 11(6):480-4.
96. Coviello AD, Legro RS, Dunaif A: Adolescent girls with polycystic ovary
syndrome have an increased risk of the metabolic syndrome associated
with increasing androgen levels independent of obesity and insulin
resistance. J Clin Endocrinol Metab 2006, 91(2):492-7.
97. Marshall JC: Obesity in adolescent girls: is excess androgen the real bad
actor? J Clin Endocrinol Metab 2006, 91(2):393-5.
98. Lewy VD, Danadian K, Witchel SF, et al: Early metabolic abnormalities in
adolescent girls with polycystic ovarian syndrome. J Pediatr 2001,
138(1):38-44.
99. Apter D, Butzow T, Laughlin GA, et al: Metabolic features of polycystic
ovary syndrome are found in adolescent girls with hyperandrogenism. J
Clin Endocrinol Metab 1995, 80(10):2966-73.
Geller et al. International Journal of Pediatric Endocrinology 2011, 2011:9
http://www.ijpeonline.com/content/2011/1/9
Page 15 of 19
100. Silfen ME, Denburg MR, Manibo AM, et al: Early endocrine, metabolic, and
sonographic characteristics of polycystic ovary syndrome (PCOS):
comparison between nonobese and obese adolescents. J Clin Endocrinol
Metab 2003, 88(10):4682-8.
101. Ibanez L, Potau N, Zampolli M, et al: Hyperinsulinemia in postpubertal
girls with a history of premature pubarche and functional ovarian
hyperandrogenism. J Clin Endocrinol Metab 1996, 81(3):1237-43.
102. Ibanez L, Potau N, Zampolli M, et al: Hyperinsulinemia and decreased
insulin-like growth factor-binding protein-1 are common features in
prepubertal and pubertal girls with a history of premature pubarche. J
Clin Endocrinol Metab 1997, 82(7):2283-8.
103. Ibanez L, Castell C, Tresserras R, et al: Increased prevalence of type 2
diabetes mellitus and impaired glucose tolerance in first-degree
relatives of girls with a history of precocious pubarche. Clin Endocrinol
(Oxf) 1999, 51(4):395-401.
104. Ibanez L, de Zegher F, Potau N: Anovulation after precocious pubarche:
early markers and time course in adolescence. J Clin Endocrinol Metab
1999, 84(8):2691-5.
105. Ibanez L, Potau N, De Zegher F: Endocrinology and metabolism after
premature pubarche in girls. Acta Paediatr Suppl 1999, 88(433):73-7.
106. Oppenheimer E, Linder B, DiMartino-Nardi J: Decreased insulin sensitivity
in prepubertal girls with premature adrenarche and acanthosis
nigricans. J Clin Endocrinol Metab 1995, 80(2):614-8.
107. Richards GE, Cavallo A, Meyer WJ, et al: Obesity, acanthosis nigricans,
insulin resistance, and hyperandrogenemia: pediatric perspective and
natural history. J Pediatr 1985, 107(6):893-7.
108. McCartney CR, Prendergast KA, Chhabra S, et al: The association of obesity
and hyperandrogenemia during the pubertal transition in girls: obesity
as a potential factor in the genesis of postpubertal hyperandrogenism. J
Clin Endocrinol Metab 2006, 91(5):1714-22.
109. Rosenfield RL: Clinical review: Identifying children at risk for polycystic
ovary syndrome. J Clin Endocrinol Metab 2007, 92(3):787-96.
110. Zumoff B, Freeman R, Coupey S, et al: A chronobiologic abnormality in
luteinizing hormone secretion in teenage girls with the polycystic-ovary
syndrome. N Engl J Med 1983, 309(20):1206-9.
111. Dale PO, Tanbo T, Djoseland O, et al: Persistence of hyperinsulinemia in
polycystic ovary syndrome after ovarian suppression by gonadotropin-
releasing hormone agonist. Acta Endocrinol (Copenh) 1992, 126(2):132-6.
112. Dunaif A, Green G, Futterweit W, et al: Suppression of hyperandrogenism
does not improve peripheral or hepatic insulin resistance in the
polycystic ovary syndrome. J Clin Endocrinol Metab 1990, 70(3):699-704.
113. Geffner ME, Kaplan SA, Bersch N, et al: Persistence of insulin resistance in
polycystic ovarian disease after inhibition of ovarian steroid secretion.
Fertil Steril 1986, 45(3):327-33.
114. Lasco A, Cucinotta D, Gigante A, et al: No changes of peripheral insulin
resistance in polycystic ovary syndrome after long-term reduction of
endogenous androgens with leuprolide. Eur J Endocrinol 1995,
133(6):718-22.
115. Diamanti-Kandarakis E, Mitrakou A, Hennes MM, et al: Insulin sensitivity
and antiandrogenic therapy in women with polycystic ovary syndrome.
Metabolism 1995, 44(4):525-31.
116. Diamanti-Kandarakis E, Mitrakou A, Raptis S, et al: The effect of a pure
antiandrogen receptor blocker, flutamide, on the lipid profile in the
polycystic ovary syndrome. J Clin Endocrinol Metab 1998, 83(8):2699-705.
117. Sahin I, Serter R, Karakurt F, et al: Metformin versus flutamide in the
treatment of metabolic consequences of non-obese young women with
polycystic ovary syndrome: a randomized prospective study. Gynecol
Endocrinol 2004, 19(3):115-24.
118. Apter D: How possible is the prevention of polycystic ovary syndrome
development in adolescent patients with early onset of
hyperandrogenism. J Endocrinol Invest 1998, 21(9):613-7.
119. Carmina E, Orio F, Palomba S, et al: Endothelial dysfunction in PCOS: role
of obesity and adipose hormones. Am J Med 2006, 119(4):356 e1-6.
120. Lakhani K, Hardiman P, Seifalian AM: Intima-media thickness of elastic and
muscular arteries of young women with polycystic ovaries. Atherosclerosis
2004, 175(2):353-9.
121. Vryonidou A, Papatheodorou A, Tavridou A, et al: Association of
hyperandrogenemic and metabolic phenotype with carotid intima-
media thickness in young women with polycystic ovary syndrome. J Clin
Endocrinol Metab 2005, 90(5):2740-6.
122. Goodarzi MO, Korenman SG: The importance of insulin resistance in
polycystic ovary syndrome. Fertil Steril 2003, 80(2):255-8.
123. Salmi DJ, Zisser HC, Jovanovic L: Screening for and treatment of
polycystic ovary syndrome in teenagers. Exp Biol Med (Maywood) 2004,
229(5):369-77.
124. Hoeger KM, Kochman L, Wixom N, et al: A randomized, 48-week, placebo-
controlled trial of intensive lifestyle modification and/or metformin
therapy in overweight women with polycystic ovary syndrome: a pilot
study. Fertil Steril 2004, 82(2):421-9.
125. Huber-Buchholz MM, Carey DG, Norman RJ: Restoration of reproductive
potential by lifestyle modification in obese polycystic ovary syndrome:
role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab
1999, 84(4):1470-4.
126. Kiddy DS, Hamilton-Fairley D, Bush A, et al: Improvement in endocrine
and ovarian function during dietary treatment of obese women with
polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992, 36(1):105-11.
127. Hoeger KM: Obesity and lifestyle management in polycystic ovary
syndrome. Clin Obstet Gynecol 2007, 50(1):277-94.
128. Palomba S, Giallauria F, Falbo A, et al: Structured exercise training
programme versus hypocaloric hyperproteic diet in obese polycystic
ovary syndrome patients with anovulatory infertility: a 24-week pilot
study. Hum Reprod 2008, 23(3):642-50.
129. Azziz R, Carmina E, Dewailly D, et al: The Androgen Excess and PCOS
Society criteria for the polycystic ovary syndrome: the complete task
force report. Fertil Steril 2009, 91(2):456-88.
130. Carmina E, Bucchieri S, Esposito A, et al: Abdominal fat quantity and
distribution in women with polycystic ovary syndrome and extent of its
relation to insulin resistance. J Clin Endocrinol Metab 2007, 92(7):2500-5.
131. Wabitsch M, Hauner H, Heinze E, et al: Body fat distribution and steroid
hormone concentrations in obese adolescent girls before and after
weight reduction. J Clin Endocrinol Metab 1995, 80(12):3469-75.
132. Reinehr T, de Sousa G, Roth CL, et al: Androgens before and after weight
loss in obese children. J Clin Endocrinol Metab 2005, 90(10):5588-95.
133. Hoeger K, Davidson K, Kochman L, et al: The impact of metformin, oral
contraceptives, and lifestyle modification on polycystic ovary syndrome
in obese adolescent women in two randomized, placebo-controlled
clinical trials. J Clin Endocrinol Metab 2008, 93(11):4299-306.
134. Otta CF, Wior M, Iraci GS, et al: Clinical, metabolic, and endocrine
parameters in response to metformin and lifestyle intervention in
women with polycystic ovary syndrome: a randomized, double-blind,
and placebo control trial. Gynecol Endocrinol 2010, 26(3):173-8.
135. Pasquali R, Gambineri A, Biscotti D, et al: Effect of long-term treatment
with metformin added to hypocaloric diet on body composition, fat
distribution, and androgen and insulin levels in abdominally obese
women with and without the polycystic ovary syndrome. J Clin
Endocrinol Metab 2000, 85(8):2767-74.
136. Eid GM, Cottam DR, Velcu LM, et al: Effective treatment of polycystic
ovarian syndrome with Roux-en-Y gastric bypass. Surg Obes Relat Dis
2005, 1(2):77-80.
137. Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, et al: The
polycystic ovary syndrome associated with morbid obesity may resolve
after weight loss induced by bariatric surgery. J Clin Endocrinol Metab
2005, 90(12):6364-9.
138. Escobar-Morreale HF: Polycystic ovary syndrome: treatment strategies
and management. Expert Opin Pharmacother 2008, 9(17):2995-3008.
139. Schilling PL, Davis MM, Albanese CT, et al: National trends in adolescent
bariatric surgical procedures and implications for surgical centers of
excellence. J Am Coll Surg 2008, 206(1):1-12.
140. Martin KA, Chang RJ, Ehrmann DA, et al: Evaluation and treatment of
hirsutism in premenopausal women: an endocrine society clinical
practice guideline. J Clin Endocrinol Metab 2008, 93(4):1105-20.
141. Nader S, Diamanti-Kandarakis E: Polycystic ovary syndrome, oral
contraceptives and metabolic issues: new perspectives and a unifying
hypothesis. Hum Reprod 2007, 22(2):317-22.
142. Ehrmann DA: Polycystic ovary syndrome. N Engl J Med 2005,
352(12):1223-36.
143. Schindler AE: Differential effects of progestins on hemostasis. Maturitas
2003, 46(Suppl 1):S31-7.
144. Cassidenti DL, Paulson RJ, Serafini P, et al: Effects of sex steroids on skin 5
alpha-reductase activity in vitro. Obstet Gynecol 1991, 78(1):103-7.
Geller et al. International Journal of Pediatric Endocrinology 2011, 2011:9
http://www.ijpeonline.com/content/2011/1/9
Page 16 of 19
145. Hammond GL, Rabe T, Wagner JD: Preclinical profiles of progestins used
in formulations of oral contraceptives and hormone replacement
therapy. Am J Obstet Gynecol 2001, 185(2 Suppl):S24-31.
146. Franks S, Layton A, Glasier A: Cyproterone acetate/ethinyl estradiol for
acne and hirsutism: time to revise prescribing policy. Hum Reprod 2008,
23(2):231-2.
147. Givens JR, Andersen RN, Wiser WL, et al: Dynamics of suppression and
recovery of plasma FSH, LH, androstenedione and testosterone in
polycystic ovarian disease using an oral contraceptive. J Clin Endocrinol
Metab 1974, 38(5):727-35.
148. van der Vange N, Blankenstein MA, Kloosterboer HJ, et al: Effects of seven
low-dose combined oral contraceptives on sex hormone binding
globulin, corticosteroid binding globulin, total and free testosterone.
Contraception 1990, 41(4):345-52.
149. De Leo V, Di Sabatino A, Musacchio MC, et al: Effect of oral contraceptives
on markers of hyperandrogenism and SHBG in women with polycystic
ovary syndrome. Contraception 2010, 82(3):276-80.
150. Mastorakos G, Koliopoulos C, Creatsas G: Androgen and lipid profiles in
adolescents with polycystic ovary syndrome who were treated with two
forms of combined oral contraceptives. Fertil Steril 2002, 77(5):919-27.
151. Heiner JS, Greendale GA, Kawakami AK, et al: Comparison of a
gonadotropin-releasing hormone agonist and a low dose oral
contraceptive given alone or together in the treatment of hirsutism. J
Clin Endocrinol Metab 1995, 80(12):3412-8.
152. Trent ME, Rich M, Austin SB, et al: Fertility concerns and sexual behavior
in adolescent girls with polycystic ovary syndrome: implications for
quality of life. J Pediatr Adolesc Gynecol 2003, 16(1):33-7.
153. Dahlgren E, Friberg LG, Johansson S, et al: Endometrial carcinoma; ovarian
dysfunction–a risk factor in young women. Eur J Obstet Gynecol Reprod
Biol 1991, 41(2):143-50.
154. Iatrakis G, Tsionis C, Adonakis G, et al: Polycystic ovarian syndrome, insulin
resistance and thickness of the endometrium. Eur J Obstet Gynecol Reprod
Biol 2006, 127(2):218-21.
155. Pillay OC, Te Fong LF, Crow JC, et al: The association between polycystic
ovaries and endometrial cancer. Hum Reprod 2006, 21(4):924-9.
156. Lurie G, Thompson P, McDuffie KE, et al: Association of estrogen and
progestin potency of oral contraceptives with ovarian carcinoma risk.
Obstet Gynecol 2007, 109(3):597-607.
157. Grimes DA, Economy KE: Primary prevention of gynecologic cancers. Am
J Obstet Gynecol 1995, 172(1 Pt 1):227-35.
158. Costello M, Shrestha B, Eden J, et al: Insulin-sensitising drugs versus the
combined oral contraceptive pill for hirsutism, acne and risk of diabetes,
cardiovascular disease, and endometrial cancer in polycystic ovary
syndrome. Cochrane Database Syst Rev 2007, , 1: CD005552.
159. Mastorakos G, Koliopoulos C, Deligeoroglou E, et al: Effects of two forms of
combined oral contraceptives on carbohydrate metabolism in
adolescents with polycystic ovary syndrome. Fertil Steril 2006, 85(2):420-7.
160. Baillargeon JP, McClish DK, Essah PA, et al: Association between the
current use of low-dose oral contraceptives and cardiovascular arterial
disease: a meta-analysis. J Clin Endocrinol Metab 2005, 90(7):3863-70.
161. Khader YS, Rice J, John L, et al: Oral contraceptives use and the risk of
myocardial infarction: a meta-analysis. Contraception 2003, 68(1):11-7.
162. Burkman RT: Hormone replacement therapy. Current controversies.
Minerva Ginecol 2003, 55(2):107-16.
163. Keeling D: Combined oral contraceptives and the risk of myocardial
infarction. Ann Med 2003, 35(6):413-8.
164. Barbieri RL: Update in female reproduction: a life-cycle approach. J Clin
Endocrinol Metab 2008, 93(7):2439-46.
165. Fryer LG, Parbu-Patel A, Carling D: The Anti-diabetic drugs rosiglitazone
and metformin stimulate AMP-activated protein kinase through distinct
signaling pathways. J Biol Chem 2002, 277(28):25226-32.
166. Checa MA, Requena A, Salvador C, et al: Insulin-sensitizing agents: use in
pregnancy and as therapy in polycystic ovary syndrome. Hum Reprod
Update 2005, 11(4):375-90.
167. Kashyap S, Wells GA, Rosenwaks Z: Insulin-sensitizing agents as primary
therapy for patients with polycystic ovarian syndrome. Hum Reprod 2004,
19(11):2474-83.
168. la Marca A, Egbe TO, Morgante G, et al: Metformin treatment reduces
ovarian cytochrome P-450c17alpha response to human chorionic
gonadotrophin in women with insulin resistance-related polycystic ovary
syndrome. Hum Reprod 2000, 15(1):21-3.
169. La Marca A, Artensio AC, Stabile G, et al: Metformin treatment of PCOS
during adolescence and the reproductive period. Eur J Obstet Gynecol
Reprod Biol 2005, 121(1):3-7.
170. Lord JM, Flight IH, Norman RJ: Metformin in polycystic ovary syndrome:
systematic review and meta-analysis. BMJ 2003, 327(7421):951-3.
171. Velazquez EM, Mendoza S, Hamer T, et al: Metformin therapy in polycystic
ovary syndrome reduces hyperinsulinemia, insulin resistance,
hyperandrogenemia, and systolic blood pressure, while facilitating
normal menses and pregnancy. Metabolism 1994, 43(5):647-54.
172. Legro RS, Barnhart HX, Schlaff WD, et al: Clomiphene, metformin, or both
for infertility in the polycystic ovary syndrome. N Engl J Med 2007,
356(6):551-66.
173. Vanky E, Stridsklev S, Heimstad R, et al: Metformin versus placebo from
first trimester to delivery in polycystic ovary syndrome: a randomized,
controlled multicenter study. J Clin Endocrinol Metab 2010, 95(12):E448-55.
174. Ibanez L, Jaramillo AM, Ferrer A, et al: High neutrophil count in girls and
women with hyperinsulinaemic hyperandrogenism: normalization with
metformin and flutamide overcomes the aggravation by oral
contraception. Hum Reprod 2005, 20(9):2457-62.
175. Kelly CC, Lyall H, Petrie JR, et al: Low grade chronic inflammation in
women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001,
86(6):2453-5.
176. Morin-Papunen L, Rautio K, Ruokonen A, et al: Metformin reduces serum
C-reactive protein levels in women with polycystic ovary syndrome. J
Clin Endocrinol Metab 2003, 88(10):4649-54.
177. Rexrode KM, Pradhan A, Manson JE, et al: Relationship of total and
abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol 2003,
13(10):674-82.
178. Boulman N, Levy Y, Leiba R, et al: Increased C-reactive protein levels in
the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin
Endocrinol Metab 2004, 89(5):2160-5.
179. Goldstein BJ, Scalia R: Adiponectin: A novel adipokine linking adipocytes
and vascular function. J Clin Endocrinol Metab 2004, 89(6):2563-8.
180. Orio F Jr, Palomba S, Cascella T, et al: Early impairment of endothelial
structure and function in young normal-weight women with polycystic
ovary syndrome. J Clin Endocrinol Metab 2004, 89(9):4588-93.
181. Orio F Jr, Palomba S, Cascella T, et al: Improvement in endothelial
structure and function after metformin treatment in young normal-
weight women with polycystic ovary syndrome: results of a 6-month
study. J Clin Endocrinol Metab 2005, 90(11):6072-6.
182. Orio F Jr, Palomba S, Cascella T, et al: The increase of leukocytes as a new
putative marker of low-grade chronic inflammation and early
cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab
2005, 90(1):2-5.
183. Tarkun I, Arslan BC, Canturk Z, et al: Endothelial dysfunction in young
women with polycystic ovary syndrome: relationship with insulin
resistance and low-grade chronic inflammation. J Clin Endocrinol Metab
2004, 89(11):5592-6.
184. Vural B, Caliskan E, Turkoz E, et al: Evaluation of metabolic syndrome
frequency and premature carotid atherosclerosis in young women with
polycystic ovary syndrome. Hum Reprod 2005, 20(9):2409-13.
185. Diamanti-Kandarakis E, Spina G, Kouli C, et al: Increased endothelin-1
levels in women with polycystic ovary syndrome and the beneficial
effect of metformin therapy. J Clin Endocrinol Metab 2001, 86(10):4666-73.
186. Velazquez EM, Mendoza SG, Wang P, et al: Metformin therapy is
associated with a decrease in plasma plasminogen activator inhibitor-1,
lipoprotein(a), and immunoreactive insulin levels in patients with the
polycystic ovary syndrome. Metabolism 1997, 46(4):454-7.
187. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al: Indices of low-grade
chronic inflammation in polycystic ovary syndrome and the beneficial
effect of metformin. Hum Reprod 2006, 21(6):1426-31.
188. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, et al: Metformin
administration improves endothelial function in women with polycystic
ovary syndrome. Eur J Endocrinol 2005, 152(5):749-56.
189. Ibanez L, de Zegher F: Ethinylestradiol-drospirenone, flutamide-
metformin, or both for adolescents and women with hyperinsulinemic
hyperandrogenism: opposite effects on adipocytokines and body
adiposity. J Clin Endocrinol Metab 2004, 89(4):1592-7.
190. Ibanez L, de Zegher F: Low-dose flutamide-metformin therapy for
hyperinsulinemic hyperandrogenism in non-obese adolescents and
women. Hum Reprod Update 2006, 12(3):243-52.
Geller et al. International Journal of Pediatric Endocrinology 2011, 2011:9
http://www.ijpeonline.com/content/2011/1/9
Page 17 of 19
191. Arslanian SA, Lewy V, Danadian K, et al: Metformin therapy in obese
adolescents with polycystic ovary syndrome and impaired glucose
tolerance: amelioration of exaggerated adrenal response to
adrenocorticotropin with reduction of insulinemia/insulin resistance. J
Clin Endocrinol Metab 2002, 87(4):1555-9.
192. Ibanez L, Potau N, Chacon P, et al: Hyperinsulinaemia, dyslipaemia and
cardiovascular risk in girls with a history of premature pubarche.
Diabetologia 1998, 41(9):1057-63.
193. Guttmann-Bauman I: Approach to adolescent polycystic ovary syndrome
(PCOS) in the pediatric endocrine community in the U.S.A. J Pediatr
Endocrinol Metab 2005, 18(5):499-506.
194. Ibanez L, Valls C, Ferrer A, et al: Sensitization to insulin induces ovulation
in nonobese adolescents with anovulatory hyperandrogenism. J Clin
Endocrinol Metab 2001, 86(8):3595-8.
195. Ibanez L, Ong K, Ferrer A, et al: Low-dose flutamide-metformin therapy
reverses insulin resistance and reduces fat mass in nonobese
adolescents with ovarian hyperandrogenism. J Clin Endocrinol Metab
2003, 88(6):2600-6.
196. Ibanez L, Potau N, Francois I, et al: Precocious pubarche, hyperinsulinism,
and ovarian hyperandrogenism in girls: relation to reduced fetal growth.
J Clin Endocrinol Metab 1998, 83(10):3558-62.
197. Ibanez L, Valls C, Potau N, et al: Sensitization to insulin in adolescent girls
to normalize hirsutism, hyperandrogenism, oligomenorrhea,
dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin
Endocrinol Metab 2000, 85(10):3526-30.
198. Vrbikova J, Hill M, Starka L, et al: The effects of long-term metformin
treatment on adrenal and ovarian steroidogenesis in women with
polycystic ovary syndrome. Eur J Endocrinol 2001, 144(6):619-28.
199. la Marca A, Morgante G, Paglia T, et al: Effects of metformin on adrenal
steroidogenesis in women with polycystic ovary syndrome. Fertil Steril
1999, 72(6):985-9.
200. Bridger T, MacDonald S, Baltzer F, et al: Randomized placebo-controlled
trial of metformin for adolescents with polycystic ovary syndrome. Arch
Pediatr Adolesc Med 2006, 160(3):241-6.
201. Nestler JE: Metformin and the polycystic ovary syndrome. J Clin
Endocrinol Metab 2001, 86(3):1430.
202. Glueck CJ, Wang P, Fontaine R, et al: Metformin-induced resumption of
normal menses in 39 of 43 (91%) previously amenorrheic women with
the polycystic ovary syndrome. Metabolism 1999, 48(4):511-9.
203. Cusan L, Dupont A, Gomez JL, et al: Comparison of flutamide and
spironolactone in the treatment of hirsutism: a randomized controlled
trial. Fertil Steril 1994, 61(2):281-7.
204. Diamanti-Kandarakis E, Kouli C, Tsianateli T, et al: Therapeutic effects of
metformin on insulin resistance and hyperandrogenism in polycystic
ovary syndrome. Eur J Endocrinol 1998, 138(3):269-74.
205. Gambineri A, Pelusi C, Genghini S, et al: Effect of flutamide and metformin
administered alone or in combination in dieting obese women with
polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004, 60(2):241-9.
206. Ibanez L, Valls C, Ferrer A, et al: Additive effects of insulin-sensitizing and
anti-androgen treatment in young, nonobese women with
hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. J Clin
Endocrinol Metab 2002, 87(6):2870-4.
207. Ganie MA, Khurana ML, Eunice M, et al: Comparison of efficacy of
spironolactone with metformin in the management of polycystic ovary
syndrome: an open-labeled study. J Clin Endocrinol Metab 2004,
89(6):2756-62.
208. Rautio K, Tapanainen JS, Ruokonen A, et al: Effects of metformin and
ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-
obese women with polycystic ovary syndrome. Eur J Endocrinol 2005,
152(2):269-75.
209. Mitkov M, Pehlivanov B, Terzieva D: Combined use of metformin and
ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. Eur J
Obstet Gynecol Reprod Biol 2005, 118(2):209-13.
210. Morin-Papunen L, Vauhkonen I, Koivunen R, et al: Metformin versus ethinyl
estradiol-cyproterone acetate in the treatment of nonobese women
with polycystic ovary syndrome: a randomized study. J Clin Endocrinol
Metab 2003, 88(1):148-56.
211. Onalan G, Goktolga U, Ceyhan T, et al: Predictive value of glucose-insulin
ratio in PCOS and profile of women who will benefit from metformin
therapy: obese, lean, hyper or normoinsulinemic? Eur J Obstet Gynecol
Reprod Biol 2005, 123(2):204-11.
212. Yilmaz M, Biri A, Karakoc A, et al: The effects of rosiglitazone and
metformin on insulin resistance and serum androgen levels in obese
and lean patients with polycystic ovary syndrome. J Endocrinol Invest
2005, 28(11):1003-8.
213. Glueck CJ, Wang P, Fontaine R, et al: Metformin to restore normal menses
in oligo-amenorrheic teenage girls with polycystic ovary syndrome
(PCOS). J Adolesc Health 2001, 29(3):160-9.
214. Velazquez E, Acosta A, Mendoza SG: Menstrual cyclicity after metformin
therapy in polycystic ovary syndrome. Obstet Gynecol 1997, 90(3):392-5.
215. Morin-Papunen LC, Koivunen RM, Ruokonen A, et al: Metformin therapy
improves the menstrual pattern with minimal endocrine and metabolic
effects in women with polycystic ovary syndrome. Fertil Steril 1998,
69(4):691-6.
216. De Leo V, Musacchio MC, Morgante G, et al: Metformin treatment is
effective in obese teenage girls with PCOS. Hum Reprod 2006,
21(9):2252-6.
217. Glueck CJ, Aregawi D, Winiarska M, et al: Metformin-diet ameliorates
coronary heart disease risk factors and facilitates resumption of regular
menses in adolescents with polycystic ovary syndrome. J Pediatr
Endocrinol Metab 2006, 19(6):831-42.
218. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, et al: A modern medical
quandary: polycystic ovary syndrome, insulin resistance, and oral
contraceptive pills. J Clin Endocrinol Metab 2003, 88(5):1927-32.
219. Vrbikova J, Cibula D: Combined oral contraceptives in the treatment of
polycystic ovary syndrome. Hum Reprod Update 2005, 11(3):277-91.
220. Allen HF, Mazzoni C, Heptulla RA, et al: Randomized controlled trial
evaluating response to metformin versus standard therapy in the
treatment of adolescents with polycystic ovary syndrome. J Pediatr
Endocrinol Metab 2005, 18(8):761-8.
221. Ibanez L, De Zegher F: Flutamide-metformin plus an oral contraceptive
(OC) for young women with polycystic ovary syndrome: switch from
third- to fourth-generation OC reduces body adiposity. Hum Reprod 2004,
19(8):1725-7.
222. Ibanez L, de Zegher F: Flutamide-metformin plus ethinylestradiol-
drospirenone for lipolysis and antiatherogenesis in young women with
ovarian hyperandrogenism: the key role of metformin at the start and
after more than one year of therapy. J Clin Endocrinol Metab 2005,
90(1):39-43.
223. Ibanez L, Valls C, Marcos MV, et al: Insulin sensitization for girls with
precocious pubarche and with risk for polycystic ovary syndrome:
effects of prepubertal initiation and postpubertal discontinuation of
metformin treatment. J Clin Endocrinol Metab 2004, 89(9):4331-7.
224. Elter K, Imir G, Durmusoglu F: Clinical, endocrine and metabolic effects of
metformin added to ethinyl estradiol-cyproterone acetate in non-obese
women with polycystic ovarian syndrome: a randomized controlled
study. Hum Reprod 2002, 17(7):1729-37.
225. Cibula D, Fanta M, Vrbikova J, et al: The effect of combination therapy
with metformin and combined oral contraceptives (COC) versus COC
alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in
PCOS patients. Hum Reprod 2005, 20(1):180-4.
226. Poyet P, Labrie F: Comparison of the antiandrogenic/androgenic activities
of flutamide, cyproterone acetate and megestrol acetate. Mol Cell
Endocrinol 1985, 42(3):283-8.
227. Muderris II, Bayram F, Guven M: Treatment of hirsutism with lowest-dose
flutamide (62.5 mg/day). Gynecol Endocrinol 2000, 14(1):38-41.
228. Ibanez L, Jaramillo A, Ferrer A, et al: Absence of hepatotoxicity after long-
term, low-dose flutamide in hyperandrogenic girls and young women.
Hum Reprod 2005, 20(7):1833-6.
229. Ibanez L, Potau N, Marcos MV, et al: Treatment of hirsutism,
hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism
in nonobese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab
2000, 85(9):3251-5.
230. Ibanez L, Potau N, Ferrer A, et al: Anovulation in eumenorrheic, nonobese
adolescent girls born small for gestational age: insulin sensitization
induces ovulation, increases lean body mass, and reduces abdominal fat
excess, dyslipidemia, and subclinical hyperandrogenism. J Clin Endocrinol
Metab 2002, 87(12):5702-5.
231. Ibanez L, de Zegher F: Low-dose combination of flutamide, metformin
and an oral contraceptive for non-obese, young women with polycystic
ovary syndrome. Hum Reprod 2003, 18(1):57-60.
Geller et al. International Journal of Pediatric Endocrinology 2011, 2011:9
http://www.ijpeonline.com/content/2011/1/9
Page 18 of 19
232. Ibanez L, Valls C, Cabre S, et al: Flutamide-metformin plus ethinylestradiol-
drospirenone for lipolysis and antiatherogenesis in young women with
ovarian hyperandrogenism: the key role of early, low-dose flutamide. J
Clin Endocrinol Metab 2004, 89(9):4716-20.
233. Vuguin P, Saenger P, DiMartino-Nardi J: Fasting glucose insulin ratio: a
useful measure of insulin resistance in girls with premature adrenarche.
J Clin Endocrinol Metab 2001, 86(10):4618-21.
234. Silfen ME, Manibo AM, McMahon DJ, et al: Comparison of simple
measures of insulin sensitivity in young girls with premature
adrenarche: the fasting glucose to insulin ratio may be a simple and
useful measure. J Clin Endocrinol Metab 2001, 86(6):2863-8.
235. Legro RS, Finegood DT, Dunaif A: A fasting glucose to insulin ratio is a
useful measure of insulin sensitivity in women with polycystic ovary
syndrome. J Clin Endocrinol Metab 1998, 83(8):2694-8.
236. Ibanez L, Valls C, Potau N, et al: Polycystic ovary syndrome after
precocious pubarche: ontogeny of the low-birthweight effect. Clin
Endocrinol (Oxf) 2001, 55(5):667-72.
237. Ibanez L, Ferrer A, Ong K, et al: Insulin sensitization early after menarche
prevents progression from precocious pubarche to polycystic ovary
syndrome. J Pediatr 2004, 144(1):23-9.
238. Baillargeon J, Jakubowicz DJ, Iuorno MJ, et al: Effects of metformin and
rosiglitazone, along and in combination, in nonobese women with
polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil
Steril 2004, 82(4):893-902.
239. Ortega-Gonzalez C, Luna S, Hernandez L, et al: Responses of serum
androgen and insulin resistance to metformin and pioglitazone in
obese, insulin-resistant women with polycystic ovary syndrome. J Clin
Endocrinol Metab 2005, 90(3):1360-5.
240. Ehrmann DA, Schneider DJ, Sobel BE, et al: Troglitazone improves defects
in insulin action, insulin secretion, ovarian steroidogenesis, and
fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol
Metab 1997, 82(7):2108-16.
241. Tarkun I, Cetinarslan B, Turemen E, et al: Effect of rosiglitazone on insulin
resistance, C-reactive protein and endothelial function in non-obese
young women with polycystic ovary syndrome. Eur J Endocrinol 2005,
153(1):115-21.
242. Dereli D, Dereli T, Bayraktar F, et al: Endocrine and metabolic effects of
rosiglitazone in non-obese women with polycystic ovary disease. Endocr
J 2005, 52(3):299-308.
243. Seto-Young D, Paliou M, Schlosser J, et al: Direct thiazolidinedione action
in the human ovary: insulin-independent and insulin-sensitizing effects
on steroidogenesis and insulin-like growth factor binding protein-1
production. J Clin Endocrinol Metab 2005, 90(11):6099-105.
244. Glueck CJ, Moreira A, Goldenberg N, et al: Pioglitazone and metformin in
obese women with polycystic ovary syndrome not optimally responsive
to metformin. Hum Reprod 2003, 18(8):1618-25.
245. Dunaif A, Scott D, Finegood D, et al: The insulin-sensitizing agent
troglitazone improves metabolic and reproductive abnormalities in the
polycystic ovary syndrome. J Clin Endocrinol Metab 1996, 81(9):3299-306.
246. Hasegawa I, Murakawa H, Suzuki M, et al: Effect of troglitazone on
endocrine and ovulatory performance in women with insulin resistance-
related polycystic ovary syndrome. Fertil Steril 1999, 71(2):323-7.
247. Gambineri A, Semple RK, Forlani G, et al: Monogenic polycystic ovary
syndrome due to a mutation in the lamin A/C gene is sensitive to
thiazolidinediones but not to metformin. Eur J Endocrinol 2008,
159(3):347-53.
248. Franks S: When should an insulin sensitizing agent be used in the
treatment of polycystic ovary syndrome? Clin Endocrinol (Oxf) 2011,
74(2):148-51.
249. Shu Y, Sheardown SA, Brown C, et al: Effect of genetic variation in the
organic cation transporter 1 (OCT1) on metformin action. J Clin Invest
2007, 117(5):1422-31.
250. Ahlin G, Chen L, Lazorova L, et al: Genotype-dependent effects of
inhibitors of the organic cation transporter, OCT1: predictions of
metformin interactions. Pharmacogenomics J 2010.
251. Becker ML, Visser LE, van Schaik RH, et al: Genetic variation in the organic
cation transporter 1 is associated with metformin response in patients
with diabetes mellitus. Pharmacogenomics J 2009, 9(4):242-7.
252. Kajiwara M, Terada T, Ogasawara K, et al: Identification of multidrug and
toxin extrusion (MATE1 and MATE2-K) variants with complete loss of
transport activity. J Hum Genet 2009, 54(1):40-6.
253. Trent M, Austin SB, Rich M, et al: Overweight status of adolescent girls
with polycystic ovary syndrome: body mass index as mediator of quality
of life. Ambul Pediatr 2005, 5(2):107-11.
254. Trent ME, Rich M, Austin SB, et al: Quality of life in adolescent girls with
polycystic ovary syndrome. Arch Pediatr Adolesc Med 2002, 156(6):556-60.
doi:10.1186/1687-9856-2011-9
Cite this article as: Geller et al.: State of the Art Review: Emerging
Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents
with Polycystic Ovary Syndrome (PCOS). International Journal of Pediatric
Endocrinology 2011 2011:9.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Geller et al. International Journal of Pediatric Endocrinology 2011, 2011:9
http://www.ijpeonline.com/content/2011/1/9
Page 19 of 19
